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1 Executive Summary 
 
1.1 Context 
In 2018, Health and Social Care Evaluations (HASCE) at the University of Cumbria was commissioned by 
the Northern Cancer Alliance (NCA) to evaluate the delivery of the NCA programme entitled ‘Vague 
Symptoms Pathway’ (VSP). The aim of this programme was to address a perceived problem for 
patients who present to their General Practice/Practitioner (GP), unwell, but with vague symptoms 
which do not neatly fit the two-week wait criteria.1 This creates a challenge for GPs in identifying an 
appropriate route forward into secondary care for those patients.  The NCA offered a funding pot for 
some localities to bid into in order to pilot projects with the aim of creating and enabling expedited 
access to testing, and assessment for these patients, to establish whether further cancer 
investigations are required.  
 
 1.2 Methodology 
This evaluation work, which began in 2019, utilised a mixed-methods approach; using quantitative data 
collated from project returns and analysed using descriptive statistics, along with semi-structured 
interviews to collect qualitative data, which was then subjected to template analysis. The data 
collection was informed by a realist approach to evaluation; this aims to build an understanding about 
what works for whom, in what context and the mechanisms and outcomes around this.  
 
 1.3 Findings 
Below is a short summary of the key areas of findings, these are explored in more detail in the body of 
the report. 
 
1.3.1 Three project pathways 
South Tees, Sunderland and Newcastle have each designed pathways underpinned by the context 
above. All three designs seek to address the problem facing the GP, of knowing where to refer 
patients; unaddressed, this issue can lead to delays, either through monitoring patients for longer 
before referral to see how symptoms develop, or as patients are referred between specialities.    
The three areas have synergy with regard to the broad context and inherent challenges of managing 
patients with vague symptoms, however, each area has adapted its design to fit its perceived needs, 






as is summarised in the following sections. Additionally, all three projects use appropriate ‘vague’ 
symptoms in their referral criteria but have different eligibility criteria with respect to age.  
 
1.3.2 Primary and secondary care feedback on the implementation of VSP 
The evaluation has found the significant majority of clinicians and professionals with operational 
responsibilities for the intervention are enthusiastic about the pilot. What is more, some medical 
professionals, especially in radiology, have been proactive in supporting the VSP. Qualitative data 
collected from the clinicians is strongly suggestive that patients are having positive experiences of the 
intervention, although this is anecdotal. Patient experience of the programme was captured in a 
separate evaluation (see Appendix 1).  
There were initial concerns among project leaders in all pathway areas that the intervention could lead 
to a surge in patient volumes, with the potential to cause an overstretch of resources, especially in 
radiology departments. This does not appear to have been the case at the time of this evaluation.  
4.4 Primary and secondary care feedback on the implementation of VSP 
The intervention has been well received in each pathway area among all clinical groups and 
professions and the concept underpinning the intervention is widely supported. In particular, the 
pathway is seen as addressing an important gap for those patients who do not easily fit with existing 
two-week rule pathways and, also, reducing the need for multitude of investigations requested by 
primary care. 
An operational issue to note is the reported reliance on the ‘goodwill’ of hospital personnel to 
facilitate the VSP, as Radiology departments and clinical staff are often supporting the VSP on a ‘best 
efforts’ basis. This matter is also identified in MDC pilot projects (ACE Programme 2019 c, p. 4). The 
longer-term implications of this could be considered, as there appears to be an acknowledgement 
across the pathways that increases in patients could test the capacity and resources of the system to 
cope.  
4.6 Number of referrals and pathway uptake 
A total of 226 patients have been referred to a VSP during the period of this evaluation. Analysis of 
referral rates, demographic and socio-economic profiles of participating GP practices identified some 
findings that may be related to equitable access to VSP and/or provide contextual information to 
differences in performance and outcomes of different VSP projects. For example, small and large GP 
practices do not make referrals in proportion to their occurrence frequency. Small GP practices tend 
to make up to 50% fewer VSP referrals, proportionate to how often they occur in the project. Similarly, 
large practices tend to make nearly twice as many VSP referrals, proportionate to their occurrence 
frequency. This trend is consistent across projects, despite the differences between GP practices 
related to age, deprivation, ethnic and rural-urban profiles. A more detailed profile of the project areas 




1.3.5 4.9 Appropriate use of the pathway 
Referrals are reviewed in only two of the operating pathways. To date, a rejection rate of 15.4% has 
been recorded in this project. There is no significant evidence that referrals are being made 
inappropriately, although projects may not be monitoring rejection rates. 
4.10 Characteristics of patients referred to the VSP 
Data from both operating pathways identified five characteristics of patients referred to the VSP are 
summarised in this section. These characteristics are: 
 Gender: of the 226 patients referred to the VSP to date, 55% were female and 45% were male; 
and,  
 Age: 52% of all patients referred to the combined VSP projects were aged 70 or over. 
Co-morbidity data is only available for one VSP project. 
Presenting symptoms: data on how many and which symptoms each patient presented with at the 
point of referral is available from South Tees. This shows: 
 Nearly half (42%) of patients presented with one symptom; 
 Over a third (35%) presented with two; 
 17% presenting with three symptoms; and,  
 6% presenting with four symptoms. 
 
More patients (61.5%) presented with weight loss as at least one of their symptoms, than any other 
symptom.  One fifth of patients presented with fatigue (20.6%) and/or abdominal pain (19.1%) with a 
range of other symptoms following (captured in detail in the body of the report).  
It is useful to note that only 11.8% of patients presented at referral with GP ‘gut’ feeling as a symptom, 
despite this being identified as the most critical factor in referral decisions. 
 
1.3.7 4.9 Diagnostic tests 
Most patients seen in the VSP (88.5%) to date have had a CT scan of the chest, abdomen and pelvis. 
4.10 Diagnosis outcomes 
A critical area of interest is the outcomes for the patients referred on to a VSP, some headline findings 
are shared here:  
 
 The Conversion Rate (CR) – which is the proportion of VSP referrals resulting in a cancer 
diagnosis - is 10.3% (combined data) for the project to date. This is consistent with of the range 
of individual MDC project levels CRs of 4-11% and higher than the 8% CR at MDC programme (ACE 
Programme, 2019b, p. 13).  
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 A fifth of patients (21.4%) were diagnosed with a new non-cancer condition, which is lower than 
the rate reported for the MDC programme where one third of cases were diagnosed with a non-
cancer condition (ACE Programme, 2019b, p. 14). 
 Over half (55.3%) of patients were discharged as ‘all test normal’ and 9.2% of patients were either 
still undergoing ongoing tests or were still on the pathway. 3.4% of referrals were rejected and 
0.4% diagnosed a recurrence of cancer. 
 The VSP combined project CR of 10.3% exceeds the rate for all 2WW pathways for 2013/14 - 
2017/18 in Sunderland CCG (7.4%); Hambledon, Richmond and North Yorkshire CCG (9.8%) and 
England (8%) (2WW Referrals, Cancer Services, PHE).  
 
1.3.9 4.11 Types of cancer diagnosed 
Of the 28 cancers diagnosed to date as a result of referral to VSP: 
 
 14.3% were lung cancer; 
 10.7 % were haematological cancer; 
 9% were prostate, colorectal or pancreatic cancer; and, 
 One case (3.6%) of each of the other types of cancers was recorded: hepatocellular, 
angiosarcoma, gallbladder, renal, stomach, breast, oesophageal, bladder, liver cell carcinoma, 
Non-Hodgkin’s Lymphoma, lung cancer and peritoneal mesothelioma. One case of recurrent 
cancer (residual CLL) was also recorded. 
 
1.3.10 4.11.1 Common, rare and less common cancers diagnosed 
Of the cancers diagnosed by the VSP to date, 68% have been Less Common or Rare cancers, which is 
somewhat higher than the 56% of Less Common or Rare cancers diagnosed by the MDC programme 
(ACE Programme, 2019b, p. 13).  
 
1.3.11 4.12 Staging of cancers diagnosed 
A major objective for VSP projects is to improve the diagnosis of cancers at earlier stages of cancer 
and improve treatment options and outcomes and patient experiences (ACE Programme, 2017, p. 1).  
Of cancers diagnosed to date by the VSP to date, 82% have staging information, which shows that:  
 35% of cancers were diagnosed at Stage 1; 
 9% at Stage 2; 
 9% at Stage 3; and 
 48% at Stage 4. 
Overall, 44% of cancers were diagnosed at early stage (stages 1 or 2), compared to 26% in the MDC 




1.3.12 Non-cancer diagnoses 
The combined project data shows that 20.6% of patients referred to the VSP were diagnosed with a 
non-cancer condition. 
 
1.3.13 4.14 Time to diagnosis 
The median number of days from referral to the first diagnostic test in the Sunderland VSP was 13 days 
in Quarter 1 and 14 days in Quarter 2. In the South Tees VSP, the median number of days from referral 
to first diagnostic tests was 2.5 days in Quarter 1, 7 days in Quarter 2 and 3. 
The qualitative data provides a rich reflection in support of the quantitative data shared above and 
brings an understanding to the operations and benefits of the pathways, as perceived by those 
working in and around them. 
 
1.5 Conclusions and 5.3 Recommendations 
The evidence presented above illustrates that the overall aim of the programme is being met – clearly, 
the pathways present a highly appropriate and effective option to GPs when faced with a patient with 
vague symptoms. It is also evidenced via the quantitative and qualitative data that expedited access is 
generally being achieved, with those who are staffing the pathways and associated activities feeling 
very positive about their effect and potential. Importantly, that expedited access is reducing the time 
to diagnosis for patients, thus enabling more rapid care, for cancer, or identifying another condition.  
Overall, the evaluation team feel that the pathways considered here, at their individual stages, are 
successful, that the programme has been well implemented and is delivering against its core aims. 
However, in all programmes, particularly those that are piloting new approaches, lessons can be 
learned and, with this mind, thirteen recommendations arise from this evaluation report as follows: 
1. The NCA monitors uptake of the VSP by GP practices for the remainder of the project to 
identify whether further promotional activity needs to take place and to enable uptake rates 
to be captured by the programme or project leads.  
 
2. It would be useful for the programme to continue monitoring a number of metrics, to include: 
trends relating to GP practice size and proportion of VSP referrals; trends relating to GP 
practice size, age, deprivation profiles, ethnic diversity, geographic profile, are monitored with 
regard to equitable access or to provide information on performance and outcomes against 
different variables. 
 
3. Referral rejection rates are monitored throughout the project to identify whether 
repeat/revision of guidance on referral criteria or other action is needed.  
 
4. VSP configurations where minimal referral information is available and/or no clinic assessment 
is performed, consider how they can how they can obtain sufficient referral and patient 




5. The age distribution, and particularly the frequency of patients < 50 years of age, is monitored 
and investigated if the current unexpected trend continues. 
 
6. The Project Steering Group considers whether co-morbidity data for all patients on the VSP is 
essential for interpreting project results and, if so, discuss with projects whether and how this 
data can be accessed and extracted. 
 
7. The Project Steering Group considers whether performance status data is essential for 
interpreting project results and, if so, discuss with projects whether and how this data can be 
accessed and extracted.  
 
8. The project(s) continue to monitor and investigate trends and variations in the percentage of 
patients presenting with each symptom type (and particularly GP gut feel) and reports this 
data on an individual project level as well as combined data for all VSPs. 
 
9. The Project Steering Group considers whether the Detection Rate of the pathway should be 
monitored and if they wish to disseminate that information further.   
 
10. The Project Steering Group considers whether staging information linked to type of cancer 
should, and can be, provided by projects. If so, projects should be asked for staging 
information, linked to type of cancers for previous data returns. Furthermore, the data return 
form could be amended to capture this information for the remainder of the project. 
 
11. The Project Steering Group considers whether projects need to provide additional data to 
calculate the full range of metrics and, if so, to amend the data return form to collect this data. 
 
12. The Project Steering Group considers whether treatment information is required. If so, 
projects could be asked to provide treatment information relating to cancers diagnosed and 
reported to date, and the data form amended to collect this data. It is suggested that any 
amendment to the data collection form enables the type of cancer, staging and treatment to 
be linked.  
 
13. The Project Steering Group considers whether the VSP project needs to develop and 
implement a data quality assurance process to identify, correct and provide an audit trail for 







A series of local and national pilots have previously developed, tested and considered service models 
to address the needs of patients who present with Vague Symptoms (also known as ‘non-specific but 
concerning symptoms’) and who do not meet the current criteria for urgent referral to a specialist 
cancer pathway.   
These patients often experience delays reaching a diagnosis, especially as they may be referred to 
more than one clinical specialty as the diagnostic pathway progresses. The aim of the new Vague 
Symptoms Pathway (VSP) is to offer expedited access to testing and assessment to establish if further 
cancer investigations are required. Pathway objectives are to reduce time to diagnosis for patients 
with malignancy, and to screen out people who do not need to access cancer testing and services. 
The Northern Cancer Alliance (NCA) provided funding to enable the piloting of this pathway within the 
NCA geographic footprint.  Four localities (Sunderland, South Tees, South Tyneside and Newcastle) 
submitted bids for pilot projects. Three of these projects are the subject of this evaluation, with each 
project at a different stage of maturity at the time of this work. The projects can be outlined as 
follows:  
 Sunderland is an established service which has been running since September 2017 and has 
over 18 months of operational experience and data;  
 South Tees has been running for 10 months since October 2018; and,  
 Newcastle launched its pathway in June 2019 and no operational data was available at the time 
of this evaluation.  
All three projects are following guidance and implementing learning from the national ACE 
Programme and this, along with the evaluation outputs, will feed into any extension of the pathway 
into other areas, for example, North Cumbria.  
HASCE was commissioned by the NCA to evaluate and report on the implementation and emerging 
results of the three projects outlined above. The agreed approach to this work has been a mixed-
methods evaluation to bring the robustness of the quantitative data together with the richness of 
qualitative work. This combination makes for a fuller narrative of evaluation findings for the 
commissioner and the projects considered. 
 
2.1 Contextual demographic, socio-economic and cancer incidence information for projects  
At the outset, to set the scene, below is a range of contextual demographic, socio-economic, cancer 
incidence and outcome information for each of the projects. This has been extracted from the bid 
documentation submitted by the pathways to the NCA. Further specific profile data related to patients 
registered with each GP practice (GP practice size, age, deprivation, ethnic and rural-urban location) is 




City Hospitals Sunderland (CHS) is a large acute trust located within the city of Sunderland. During the 
evaluation the trust merged with South Tyneside Trust. It provides cancer services to the local 
population of approximately 330,000 people and sub-regional services to a population of up to 
850,000, depending on the subspecialty. Service delivery is supported by tertiary and regional services 
based in Newcastle providing oncology and radiotherapy for more rare cancers such as thyroid or 
leukaemia. 
CHS is the prime secondary care provider for the local population commissioned by Sunderland Clinical 
Commissioning Group (CCG), which comprises 40 local general practices. The local population is 
primarily urban or semi-urban and exhibits relative stability without significant mobility. Social 
deprivation affects a significant element of the population and there is a significant burden of 
morbidity resulting, in part, from a history of heavy industry. In 2014-15, CHS provided almost 2,000 
first treatments, with 48% of these coming from Sunderland CCG residents.  
The Radiology Service and Primary Care have previously developed a strong working relationship, 
which enable them to deliver a combined approach to pathway redesign in 2014, resulting in 
significant improvement in the local lung cancer pathway. 
Some key data relating to the Sunderland CCG locality includes: 
 The cancer incidence rate in this locality - 663.1 per 100,000 - is higher than the English average 
(606.7 per 100,000); 
 The cancer mortality rate (338.9 per 100,000) is also higher than the English average (285.4 per 
100,000); 
 The rate of people under 75 dying of cancer (classified as premature cancer deaths) in 
Sunderland (175.5 per 100,000) is higher than the English average (141.5 per 100,000); 
 One-year cancer survival in NHS Sunderland CCG (69.4%) is similar to the English average 
(70.2%); and, 
 20.9% of patients in NHS Sunderland CCG are diagnosed with cancer through emergency 
routes; this is comparable to the English average of 20.1%. However, generally higher numbers 
of patients diagnosed through emergency routes may indicate late diagnosis and may 
correlate closely with poor survival. 
 
2.1.2 South Tees 
Situated in the North East of England in the Tees Valley sub-region and the Hambleton, Richmondshire 
and Whitby areas of North Yorkshire, South Tees Hospitals NHS Foundation Trust is the largest 
hospital trust in the Tees Valley. The trust runs one acute hospital with services delivered over two 
sites, as well as services in a number of community hospitals. It provides cancer services across seven 
Local Authority areas and five CCG areas, serving a population of approximately 1.5 million people.  
This area exhibits diversity in both geography and population; the densely populated urban centres of 
Middlesbrough are in stark contrast to remote rural communities in Aysgarth, Reeth and Leyburn. 
There are levels of high social deprivation and unemployment with consequent impacts on health.  
17 
 
The James Cook University Hospital is situated in the heart of Middlesbrough and is one of Europe’s 
largest and most modern hospitals offering 80+ specialist services from one location. Numerous 
services support the prevention, diagnosis, treatment and rehabilitation of those affected by cancer 
on the James Cook Hospital and Friarage Hospital sites. 
Some key observations on South Tees:  
 Overall, the incidence of cancer is higher than national levels (in England, one in three people 
in England will develop cancer at some stage in their lives); 
 Cancer poses particular challenges to the health of the population of Middlesbrough and 
Teesside; 
 Survival rates from some cancers are among the worst in the country;  
 Cancer is a major cause of premature death in North Yorkshire and York; 
 Scarborough and Richmondshire both have an increased incidence of cancer and higher 
mortality than North Yorkshire as a whole; 
 North Yorkshire and York has an ageing population who are at increasing risk of cancer; and 
 The overall cancer incidence rate increased from 317 per 100,000 in 1993 to 373 per 100,000 in 
2009. Despite this, mortality from cancer fell over the same time period from 193.6 per 
100,000 during 1993 to 150.0 per 100,000 in 2010. 
 
2.1.3 Newcastle 
Newcastle-upon-Tyne is based in the North East of England. There are 33 GP Practices in Newcastle 
and the total practice population size is 315,905 (as at September 2018). Newcastle and Gateshead 
(the neighbouring town to Newcastle) are served by Newcastle Gateshead CCG2.  
There are high levels of deprivation within Newcastle City and its surrounding areas, with Newcastle 
being one of the 20% most deprived areas in England. The health of the people in Newcastle is 
generally worse than the England average, with life expectancy lower than the England average for 
both men and women. There are a number of factors contributing to poorer health outcomes for 
people in Newcastle, including its industrial past, high levels of social deprivation and historically high 
levels of smoking. 
The Newcastle-upon-Tyne Hospitals NHS Foundation Trust (NuTH) provides a tertiary centre for 
cancer, the Northern Centre for Cancer Care, based in the Freeman Hospital. The majority of patients 
in Newcastle diagnosed with cancer will receive treatment from NuTH, although there are several 
other hospitals in the area, which patients could choose to attend, such as Gateshead NHSFT, 
Northumbria NHSFT and City Hospitals Sunderland NHSFT. 
Some key facts on Newcastle:  
 The cancer incidence rate in Newcastle in 2014/15 was considerably higher at 609.1 per 100,000 
than the England average of 523 per 100,000. Of these cases, only 47.4% were diagnosed 
following a referral to a 2 Week Wait (2WW) pathway; 
                                                             
 
2 Some demographic data is available at a CCG level only 
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 In 2016, in the Newcastle Gateshead CCG area, only 52.5% of cancers diagnosed were detected 
at stage 1 and 2; 
 Under 75 years mortality from cancer in Newcastle Gateshead was 157.6 per 100,000, 
compared to the national average of 121.9 per 100,000 (in 2016); 
 One-year survival rates in the CCG area are 71.4% compared to the England rate of 72.3%; 
 In 2016/17, 96 per 100,000 were diagnosed with cancer following an emergency presentation, 
compared to an England average of 88 per 100,000. 
 
3 Evaluation approach 
 
This section will outline the main research questions, the methodological approach to the evaluation, 
the quantitative analysis of the project data returns, and the qualitative data collection through 
interviews with primary and secondary care staff involved with developing, implementing and 
delivering the three VSP projects that form part of this evaluation.  
 
3.1 Research questions  
The evaluation was designed to address the following research questions:  
 
1. Is the development and implementation of the participating projects to date on target to meet 
the NCA objectives? 
2. What do data from project returns to date tell us about the performance of the pathways in 
each location? 
3. Are there emerging themes and/or recommendations for the remainder of this project and for 
future VSP projects?  
 
3.2 Methodological approach 
The approach to this evaluation was based on a realist methodology, which involves forming and 
testing hypotheses on how a programme has been delivered and considers what works for whom and 
in what circumstances (Pawson, 2013).  
Baseline information about each pathway was gathered by the evaluation team via ‘scoping’ 
interviews with VSP programme leads and a sample of other leading figures responsible for 
developing the projects. These scoping interviews, together with an analysis of the complexity of the 
context(s) in which the intervention takes place using a VICTORE approach (Volitions, Implementation, 
Contexts, Time, Outcomes, Rivalry, Emerging), were used to develop a Theory of Change (Error! R
eference source not found.). Scoping interviews also informed the data collection strategy, i.e. key 




Qualitative data was collected in each of the three pilot locations of Newcastle, South Tees and 
Sunderland. The main empirical component of the qualitative evaluation involved semi-structured 
interviews with a range of personnel in both primary and secondary care involved with the 
development and delivery of the VSP. Semi-structured interview guides were designed based on the 
evaluation team’s Theory of Change model (), adapted to individual clinical specialties or professions 
and the maturity of each pilot area. 
The research design aimed to include a representative sample of professionals and clinicians working 
in a variety of key positions and roles in each pathway area. These included specialties and professions 
such as: Consultant Gastroenterologist; Strategic Cancer Lead; Macmillan Lead Cancer Nurse; 
Macmillan GP; Cancer Lead GP; VSP Project Delivery Officer; Cancer Care Co-ordinator; Cancer Services 
Manager; Cancer Improvement Manager and Consultant Radiologist. 
GPs who had used the VSP were targeted for interview based on suggestions by Project Leads. 
Referral patterns from GP surgeries were also examined to identify and target GP surgeries showing a 
range of referral patterns: 
1. Large practices with a low number of referrals 
2. Large practices with a high referral rate 
3. Small practices with a high referral rate 
4. Practices with higher proportion of older patients but low referral rates 
5. Practices with higher proportion of deprived patients but low referral rates 
6. Practices with higher rate of VSP referrals rejected or redirected 
7. ‘Average’ (ie medium size with mid-range referral rate) practices for comparison 
In total, 24 interviews were conducted for the qualitative component of the evaluation.  
Additionally, relevant information was also captured during Vague Symptoms Steering Group 
meetings (attended by members of the evaluation team) and extracted from Steering Group meeting 
minutes.  
Quantitative data about project activity and outcomes was obtained from quarterly returns provided 
by projects to NCA. Projects report pathway activity on a quarterly basis, according to an agreed 
schedule (Error! Reference source not found.): 
Quarter  Period covered Deadline for 
submission 
1 Start of pilot to include December 2018 23rd January 2019 
2 January to March 24th April 2019 
3 April to June 24th July 2019 
4 June to August 25th September 2019 
5 September to December 2nd January 2020 
6 January to March 22nd April 2020 
Table 1. Reporting schedule and deadlines for participating projects. 
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During the period of this evaluation3, two returns (Quarters 1 and 2) from Sunderland were received 
and three (Quarters 1, 2 and 3) from South Tees. The first return from Sunderland covered a 13-month 
period from the start of the pre-cursor project on 15 September 2017 to the end of the first VSP 
quarter on 31 December 2018.  The structure of the pre-cursor project, GP Direct Access to CT, was 
adopted as the structure of the VSP pilot, thus data collected during this pre-cursor project has been 
included in the data returns for the VSP pilot. The second return from Sunderland covered the quarter 
from 1 January – 31 March 2019. South Tee’s returns covered the three quarters: 1 October-31 
December 2018; 1 January -31 March 2019 and 1 April – 30 June 2019. 
The data was provided in a summary format report agreed by the Project Steering Group, based on a 
truncated version of the national ACE Programme Wave 1 VSP data items and returns. The data used 
for this report (Error! Reference source not found.) includes corrections to the original data returns, a




                                                             
 




3.3 Theory of Change 
 






This section presents the results of the qualitative and quantitative analysis of interviews with 
GPs, clinicians, Cancer Care Co-ordinators, Project Leads and other people involved in the 
development and implementation of VSPs in South Tees, Sunderland and Newcastle CCGs. It also 
presents the results of the quantitative analysis of project data. The findings are presented as 
thirteen evaluation themes: 
1. Development rationale of project pathways 
2. Pathway design 
3. Referral criteria 
4. Primary and second care feedback on the implementation of the VSP 
5. Primary and secondary care feedback on the performance of the VSP 
6. Number of referrals and pathway uptake 
7. Appropriate use of the pathway 
8. Characteristics of patients referred to the VSP 
9. Diagnostic test(s) 
10. Diagnosis outcomes 
11. Time to diagnosis 
12. Treatment 
13. Data collection by projects    
 
4.1 Development rationale of project pathways 
The rationale driving the development of the Vague Symptoms Pathways (VSPs) was found to be 
similar across the three pilot geographies examined by the evaluation. Experiences of late 
presentations, patients presenting via the route of Accident and Emergency (A&E) or being 
‘bounced’ around the system were frequently cited in the feedback received from both primary 
and secondary care personnel alike.  As one lead General Practitioner (GP) in South Tees 
explained, the thinking behind the VSP was a perception that there:  
“… were people presenting late with cancers that didn't fit into things. And 
partly it's to try and pick-up things earlier, because people presenting late and 
presenting as emergencies tend to do worse than people who are picked-up in 
the early stages”. 
Another GP commented that addressing the needs of patients with vague symptoms has 
previously been: 
‘… quite frustrating and patients can be bounced around different specialties.’  
From a primary care perspective, the establishment of a dedicated VSP has removed the 
challenge and complexity of GPs attempting to ‘align’ the symptoms of this patient cohort with 
existing two-week cancer referral pathways, as a lead GP in South Tees recounts:  
23 
 
“I suppose in the past because we haven't had a named specific service for that, 
we've just had to try and find some speciality to vaguely attach it to. If there's 
one symptom which you think is slightly more severe, or more likely to be 
indicative of the reasons behind it, you try and slip it into that specialty”. 
These difficulties faced by GPs of trying to align patient symptoms with existing pathways are 
recognised in secondary care. A secondary care manager in the Sunderland pilot acknowledged 
that:  
“… historically I think the GPs would have maybe monitored these [vague 
symptoms] patients for a little bit or they might have tried to shoehorn their 
symptoms … to fit, you know, if they thought there was maybe something going 
on in the abdomen, upper or lower GI area. Maybe they would have tried to 
shoehorn some of those symptoms to fit the two-week wait GI pathway or 
maybe it was a lung…was to give the GP the opportunity to access a scan, to 
exclude cancer when they're just not sure - to be honest with you”. 
As well as addressing this ‘shoehorning’ effect, another critical factor driving the development of 
the VSP, frequently mentioned by both primary and secondary care clinicians, is providing GPs 
with speedy access to a CT scan. A GP in South Tees explained the difficulties of accessing CT:  
“… the things we found difficult [before there was a VSP], I think; it's just the 
power of a GP to request something like a CT scan, quickly”. 
A lead GP in the Sunderland geography also had a similar experience, noting that GPs in a 
neighbouring CCG had access to diagnostic tests unavailable in their area: 
“… if you take Durham and a patient comes and tells me that the symptom in 
question is not resolving and the chest x-ray is fine but I'm not happy, I can refer 
them to a CT chest, whereas we cannot do that here. … So we can't have access 
to all the diagnostics for various reasons. Anyway, there was clearly a missing link 
in the jigsaw there [Lead General Practitioner]”. 
A lead GP in the Newcastle pilot explained that the establishment of the VSP would facilitate a 
more structured referral process, beneficial to both primary care professionals and patients: 
“I know the [vague symptoms] patients I’ve seen; that I didn’t have a pathway, 
so historically I can see how my patients would have done better as I didn’t have 
this scan [available] in this system. … I had to then refer urgently … to a 
Consultant who may or may not have seen them quickly  … so essentially we’re 
making this more of a rational process for the patient and for primary care”. 
Clearly defined outcomes envisaged for the VSP have been identified in each of the pilot areas. A 
participant who was involved in the developmental work and implementation of the VSP in 
Sunderland stated that the clinical focus needed to remain on the essence of the intervention, 
that is, to ensure that the correct diagnosis of patient symptoms has been achieved regarding 
any suspected malignancy: 
“… when we first embarked on this project we were conscious that you do a CT 
thorax abdomen pelvis, there could be lots of incidental illness, lots of incidental 
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findings. Then you almost begin to report every single detail. Then you could 
potentially lose the central question of: has this patient got any malignancy 
based on what you see? We were very clear right from the beginning”. 
The primary outcome in all pathways is the equitable access to cancer diagnosis and treatment 
for vague symptoms patients comparable with other patient cohorts. A lead primary care 
clinician in the Newcastle pathway commented that:  
“…for patients it is hoped that the VSP will lead to equitability of treatment for 
all patients, in particular those with non-specific or vague symptoms”.  
In this regard, the intervention aims to contribute to the outcome of reducing the: 
“huge delays for patients, missed or delayed diagnoses and therefore worse 
outcomes’ [a Newcastle GP]”.  
Improving the patient care and their experience more generally has also been a motivating factor 
propelling the development of the VSP. A lead General Practitioner in the Sunderland pilot 
commented that:   
“…we would also want to reduce patient litigations, patient complaints, patient 
dissatisfaction and increase their satisfaction levels with quick and early 
diagnosis”. 
In summary, across there is agreement in all three project areas there is the perception of a 
problem for patients who present with vague symptoms. These can be summarised thus: it can 
be difficult for GPs to know to which speciality or pathway to refer patients, which can lead to 
delays, either as patients are monitored patients for longer before referral to see how symptoms 
develop, or as patients are referred between specialities.   
 
4.2 Pathway design 
The pathway design, for example, patient assessment; referral mechanism; responsibility for 
patient care, together with governance and plans for future development of the VSP differs 
slightly between each project. 
 
4.2.1 South Tees  
The pilot commenced on the 5th November 2018, with three GP surgeries and one comparator 
GP practice included in the initial roll out. This meant that the project was available to patients in 
Hambleton, Richmondshire and Whitby CCG. 
On presentation, GP ‘gut instinct’ or ‘clinical suspicion’ appears to be a key factor informing 
diagnosis of patient symptoms. Assessment of the patients begins with a first screening of 
bloods, which is carried out within Primary Care. If a patient’s symptoms align with the vague 
symptoms criteria they are referred to the VSP. Patients are referred to the pathway via ‘choose 
and book’. A new referral form has also been developed for this process.  
25 
 
A key component of this pathway is the dedicated Cancer Care Co-ordinator (CCC), who makes 
‘first contact’ with patients referred to the VSP clinic (based in Ambulatory Care at the Friarage 
Hospital). Initially at the clinic, a full examination of the patient is conducted and their clinical 
history assessed. Following this initial consultation, the consultant decides the next steps which 
can include undertaking a second level screening of bloods, a CT scan (Chest, Abdomen and 
Pelvis), Endoscopy or Haematology (or other) referral. The role of the CCC is to ensure that 
medical professionals follow up the findings of these tests and patients are kept informed about 
each stage of their journey along the pathway. 
Before a patient is discharged, a virtual Multi-Disciplinary Team (vMDT) process is initiated. This is 
a key feature of the South Tees pathway model. The CCC emails the vMDT group with a summary 
of patient results for clinical decision. A Word document or template is circulated which used to 
capture clinicians’ recommendations for each patient. These include:  
 No evidence of cancer and the patient is discharged back to their GP;  
 A site specific cancer is identified and the patient is referred to a 62-day pathway;  
 Referral of the patient to other specialty.  
The CCC maintains contact with the patients throughout, until they are discharged from the 
pathway. The aim of this is so that patients are kept informed about practical matters and 
support can be provided to alleviate anxiety and stress. 
This pathway has been designed to ensure patients receive a definitive diagnosis of cancer or 
that cancer is excluded within 28-days of referral. 
In summary, the South Tees pathway design aligns with the key design principles of a cancer 
diagnosis service (model 1) (ACE Programme, 2019a, p. 3). 
A Vague Symptoms Project Steering Group has been established to oversee and take forward the 
development of the VSP. All of the key individuals and organisations from primary and secondary 
care, along with managerial colleagues, are members of the steering group. This is consistent 
with the recommendations for successful implementation of these types of pathways (ACE 
Programme, 2019c, pp. 2; 3; 5): 
 Ensure organisational commitment and ownership of the project; 
 Maintain inter/intra organisational relationships including the most important relationship 
between primary and secondary care; and  
 The need to communicate with clinical staff and other stakeholders, usually through a 
steering group platform. 
In terms of future development, the intention is to roll out the VSP across the Middlesbrough and 
South Tees geography. The lack of dedicated resources to support this pathway has required a 
measured and phased roll out.  
The A&E phase of the pilot, to be based at James Cook Hospital, has yet to be rolled out. 
Development of the A&E component of the VSP is still at the discussion stage in South Tees. This 
development process may take time, as there are limited resources available to support 
implementation of this phase. In terms of practical steps, a new team of clinicians will need to be 
brought together to develop and implement the A&E component. There is also an awareness 
that A&E personnel do not currently have the capacity to absorb the extra workload of the 
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prospective pathway. This is a particular concern, as James Cook Hospital serves a large 
conurbation, which could lead to a large number of referrals being generated by this pathway, 
which could potentially place a strain on the resources of Radiology. 
It is evident at this stage that the South Tees pathway is a smaller scale pilot compared with the 
urban-based pathways at Sunderland, which covers most or a significant proportion of the CCG 
geographies of these areas. The South Tees practices cover large rural areas and smaller centres, 
compared with the other city scale pathways. Patients at these practices often stay with the 
same GP or Practice from ‘cradle to grave’. 
In addition, it is evident that the South Tees VSP is being rolled out slowly and in a staged 
manner, with an initial small pilot established that will inform wider iterative development across 
a broader geographical area. The relatively slow roll out is mainly due to limited resources, as well 
as a desire to learn as the process develops. In this regard, consultants and clinical staff support 
the VSP on a ‘best efforts’ basis, as the pathway is not built into their current job roles and 
planned workloads. In addition, this staged roll out aims to ensure that the capacity of the 
pathway is not exceeded, assist with identification of early problems with service delivery and 
enable monitoring of GP uptake of the pathway. 
It is evident that the CCC has a pivotal ‘lynchpin’ role in the smooth and effective operation of the 
pathway, both in terms of supporting and managing patients and as an intermediary or facilitator 
between primary and secondary care. It is envisaged that the CCC will also play a critical role in 
delivery of core outcomes of the pathway, in particular, ‘enhancing patient experience’ by 
providing personal support to each patient. 
A communications strategy has been developed by the Pathway team that is designed for both 
internal and external stakeholders. There is an emphasis on effective communication with 
patients and among the leading players with operational responsibility for the pathway. Patient 
experiences will be captured by a patient questionnaire and likewise that of GPs.  
 
4.2.2 Sunderland  
Of the three pathways, Sunderland’s is the most mature and established, building on a scheme 
for direct access to CT scans in operation in 2017.  Patients were involved in informing the design 
of this pathway following a presentation to, and feedback from, a meeting of cancer survivors in 
2018. Referral or inclusion criteria for the pathway were developed in collaboration with General 
Practitioners and the CCG (Error! Reference source not found.). 
The first stage of the pathway involves GPs arranging an initial screening of bloods and urine 
tests. In cases where abnormalities are identified, patient referrals are made via the ICE system4 
for a CT scan of the Chest, Abdomen and Pelvis with contrast. Internal escalation of positive 
                                                             
 
4 CliniSys ICE (Integrated Clinical Environment) is a suite of interoperable technologies that enables different patient care 
units to communicate with a wide range of ancillary and clinical departments such as laboratory and radiology. 
Additionally, web-based services deliver comprehensive messaging capabilities for use in primary, community and 
secondary care facilities. See: http://www.clinisys.co.uk/gb/en/solutions/electronic-requesting-results-reporting/. 
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findings suggestive of malignancy is undertaken by the Radiology Department to the relevant 
subspecialty for Outpatient review and MDT discussion.  
The Sunderland VSP aligns with the key design principles for model 2 ‘Y/N cancer diagnostic 
service’ (ACE Programme, 2019a, p. 4). 
A specific feature of the Sunderland pathway is that the reporting process for VSP CT scans are 
reported by two consultant radiologists (where possible) as a quality assurance and safety-
netting measure. Any urgent or unexpected findings are communicated to the GP in line with the 
Radiology Department’s ‘Standard Operating Procedure for the Notification of Unexpected or 
Urgent Findings.’ Patients with negative findings are reviewed by their GP and a decision is made 
for expectant management or referral to the relevant subspecialty on the basis of the screening 
information and clinical assessment.  
Given that ‘vague symptoms patients’ tend to have some imaging performed, it is expected that 
over its lifetime, the new pathway will not generate a significant increase in imaging requests. 
Instead, imaging requests will simply arise from a different source. However, there are potential 
resource implications associated with scheduling examinations, reporting, communication with 
patients and GPs, onward referrals and subsequent tracking. Until July 2019, this pathway design 
did not include a CCC and therefore one benefit of this pathway design is that it does not require 
any additional staff training, saving time and resources. However, recruitment for a CCC started 
in July 2019, which will increase the cost of this pathway design as well as enhancing the patient 
experience. 
Pathway design has incorporated patient co-development as part of the iterative development of 
the pathway. A group of patients have committed to commenting on their experiences for this 
purpose and patient questionnaires are analysed. 
Furthermore, GPs also have filled-in evaluation forms about their experiences of the pathway to 
date. 
Initially, the close working relationship between the Radiology Department and CCG meant that 
the pathway operated without a co-ordinator or navigator role to guide and support the patient 
through the process. As a result, care of and responsibility for the patient remains within primary 
care, until the point of referral to a specialty. However, recruitment for a coordinator role 
commenced in July 2019. 
Unlike the other pathways, access to the Sunderland pathway is not restricted to patients within 
a specific age range and is open to all adults. 
 
4.2.3 Newcastle 
The Newcastle VSP is at a formative stage of development and is the least advanced of the three 
pathways and is to be based on the Oxford SCAN model.  
Referral criteria (Error! Reference source not found.) are applied to eligible patients i.e. aged 40 y
ears and over. At this stage, Newcastle have not added ‘abnormal test results’ to their pathway 
criteria as it is deemed as being too vague and unclear. 
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The initial bloods are undertaken by the GP. If abnormalities in the patient are detected and there 
is a need for onward referral, the GP is responsible for arranging a CT scan. 
It is important to note that GPs can currently access CT scans but this is taking place in an ‘ad-hoc’ 
matter. As a result, this pathway aims to formalise this existing informal referral process.  
The extra funding obtained from the NCA will fund a CCC to be based in the Radiology 
Department. The role of the CCC will involve acting on the outcomes of abnormal scans and 
ensuring that patients with suspected cancers are fast tracked onto appropriate tumour 
pathways. In addition, the results of these CT scans will be communicated to primary care. 
Specifically, the CCC will be responsible for contacting patients and arranging appointments at 
hospital and informing primary care, including ensuring that GPs send a referral letter to the 
hospital containing the patient’s full medical information. There has been discussion within the 
Newcastle team about effective communication with the patient, in order to alleviate the stress 
of being informed they are on a pathway for suspected cancer. In this regard, the patient is given 
a letter informing them as to why they are being referred for a CT scan in an effort to pre-empt 
any concerns and alleviate their anxiety. 
If a scan identifies an abnormality that is not a cancer, the patient is referred back to their GP, 
who will then determine the next steps. In summary, the Newcastle pathway design aligns with 
the key design principles of a cancer diagnosis service (model 1) (ACE Programme, 2019a, p. 3).  
There is a Steering Group or Team within secondary care who are working with hospital 
departments to obtain feedback about any potential impacts, especially the management of 
patient flow and demand generated by the pathway. There is another grouping composed of 
primary care professionals, who are examining the process from their sectoral point of view. 
Initial feedback suggests that because this work is viewed as sector specific, it should be carried 
forward in this dual way. A Cancer Services Manager performs a ‘co-ordinating’ role between the 
two groups; although it is not clear whether this is a formal role in terms of the governance of 
the pathway. It is not clear at this stage if these are development task groups and whether new 
governance structures will be established once the pathway is operational. 
The implementation of the full pathway has been delayed until March 2020 to allow every 
department in Newcastle hospitals an opportunity to provide feedback and allay any concerns 
within secondary care about issues such as the potential for high numbers of referrals that may 
overstretch existing capacity.  
Consequently, the plan is to roll out the pathway on a practice-by-practice basis so that the 
number of referrals will slowly increase as the pathway becomes established and is capable of 
accepting more patients. The ‘guesstimate’ is that approximately 300 – 500 referrals per year will 
be generated by this pathway, although this a viewed as a tentative figure. 
In summary, the Newcastle approach is consistent with ACE Programme recommendations (ACE 
Programme, 2019c, pp. 2; 3; 5) for successful implementation of this type of pathway: 
 Ensure organisational commitment and test receptiveness to change prior to 
commencing; 
 Ensure key stakeholders have sufficient time to deliver their responsibilities; and 




The Northern Cancer Alliance patient questionnaire will be utilised to collect patient’s feedback 
and experiences of the pathway.  
There is a sense that the Newcastle model is creating a formal diagnostic framework for both 
patients and practitioners to replace the current ad-hoc referral arrangements. Patients are 
already being referred for CT Scans by GPs and the objective is to provide these patients with a 
structured pathway that will lead to speedier diagnoses.   
Also built into the Newcastle pathway is the use of an ‘advice and guidance’ protocol, which is 
already in place at the CCG. For instance, if a GP has concerns about a patient who does not meet 
all of the specific symptomatic criteria necessary for escalation, the hospital should be contacted 
and advice sought about how best to manage their situation. This protocol aims to provide an 
additional layer of ‘safety-netting’ for patients.  At this stage, it is not clear whether the 
Newcastle model has an MDT component. 
In summary, each project has a slightly different pathway design but these are consistent with 
the design principles identified in the ACE Programme review of Emerging models and principles 
of MDC projects (ACE Programme, 2019a, pp. 3-5).  
 
4.3 Referral criteria 
Referral criteria for all three pathways are based on the commonly accepted group of ‘vague’ or 
‘concerning but not-specific symptoms’ (ACE Programme, 2017, p. 1), with varying levels of 
specificity:  
 Unexpected weight loss 
 Severe unexplained fatigue 
 Onset of persistent nausea and appetite loss 
 Emergence of pain/discomfort of unknown ætiology  
Projects vary in the use of age limits to determine patient eligibility. The Sunderland VSP is 
available to all adults (i.e. greater than 18 years). South Tees have set an eligibility age limit of 
greater than 30 years and Newcastle have targeted their pathway at an older cohort of patients 




 Sunderland South Tees Newcastle 
Symptom 
category 
Other symptoms causing GP tend to 
have a high suspicion of malignancy, 
(often described as GP’s “gut 
feeling”) 
GP suspicion / concern GP gut feeling 
 
Gut feel Unexplained weight loss >5% within 
the preceding 3 months 
Age 30+ unintentional weight 
loss (patients that have other 
symptoms and fulfil 2WW rule 
criteria for upper and lower GI 
must be referred using current 
pathways) 
Unexpected weight 




Recent or progressive pain of 
unexplained aetiology of more than 
four weeks duration 
Age 30+, Non-specific recent 
onset abdominal 
pain/discomfort with no 
associated change in bowel 
habit (must not fulfil criteria for 
any other 2WW rule pathway or 
had previous investigations for 
chronic abdominal pain) 
New atypical pain 
 
Pain Severe constitutional symptoms e.g. 
fatigue, nausea, sweats of unknown 
aetiology  of more than 4 weeks 
duration 
Age 30+ persistent nausea/ loss 
of appetite (do not fulfil criteria 
for 2 WW GI referral)  







Fatigue (as above) Age 30+ persistent fatigue that 
is significantly altering a patients 
quality of life ( must not have 
undergone investigations or 





 Patient is unsuitable for another 
urgent or two-week wait system 
pathway based on the GPs 





1. Known contraindication to 
intravenous contrast media which 
would include a GFR less than 45 
2. Known allergy to contrast media 
3. Known risk of contrast induced 
nephropathy 
4. Morbid obesity 
5. Age under 18 years 
  
Table 2. Referral criteria for Sunderland, South Tees and Newcastle VSP projects. 
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Interviews with VSP project members identified GP ‘gut feeling’ or clinical suspicion as an 
important, if not, the critical criterion in the assessment of potential alarm-symptoms 
experienced by patients. As a secondary care clinician in the South Tees pilot explained:  
“We carefully thought through our inclusion criteria … the most important 
criteria is GP suspicion”. 
From a primary care perspective, clinical suspicion is also often viewed as the determining factor 
when deciding to refer a patient. Exploiting these instinctive diagnostic skills is key:  
“I think a lot of GPs really have quite good levels of suspicion and diagnostic 
skills. So it's really to try and harness that and to channel that forward, allowing 
us to still raise alarm bells even if it doesn't meet the direct two-week rule 
criteria” [A South Tees GP]. 
A GP in South Tees outlined how they have made referrals of patients who have presented with 
vague symptoms: 
“I think it's where there's no specific indications for a two-week rule referral, or 
there's no specific signs so that you know exactly which speciality to go for, but 
you have a gut feeling. Maybe the non-specific symptoms that your patient has 
might add up to something a little bit more than meets the eye”. 
A lead GP in Sunderland explained the range of alarm symptoms that patients present with, 
which can trigger a high level of clinical suspicion among GPs: 
“Basically, this pathway aims at identifying people who do not meet the two-
week criteria, but where there is a high clinical suspicion of cancer and we 
objectified that in certain ways where we said the patient should have lost about 
five percent of their body weight over a three-month period. Constitutional 
symptoms like myalgia, generalised aches and pains, bone pains, night sweating. 
All of these non-specific symptoms”. 
However, analysis of data on ‘4.10.5 Presenting symptoms’ shows that overall only 11.8% of 
patients were recorded as having GP ‘gut feel’ as a presenting symptom, although this figure 
differed between the two projects. Thus, in South Tees, 26.9% of patients were recorded with GP 
‘gut feel’ as at least one of their presenting symptoms, whereas in Sunderland the corresponding 
figure was 8.1%.  
The majority of patients (61.5% of all patients referred to the VSP in both projects) were recorded 
with weight loss as one of their presenting symptoms (48.1% in the South Tees VSP, 64.8% in 
Sunderland VSP).  
Feedback on referral criteria from one senior secondary care clinician identified potential 
ambiguity in applying weight loss as a diagnostic criterion:  
“I had a bit of an issue [in relation to the referral criteria] because one of the 
symptoms that goes through the vague symptom pathway is weight loss. And to 
my mind that's a two-week rule referral”.  
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It is important to note that the evaluation has not found any challenges or detected only one 
instance of some wider clinical concern associated with applying this criterion in the three pilot 
locations. However, from a precautionary standpoint, a process of ongoing reassessment of the 
efficacy of each of the referral criteria, based on experiential learning, could be applied as each 
pathway evolves and matures going forward.  
In summary, all three projects use appropriate ‘vague’ symptoms in their referral criteria but have 
different eligibility criteria with respect to age. Whilst, interview data suggests that ‘GP gut feel’ 
is a critical aspect of the decision to refer patients to the VSP, for most patients (61.5%) weight 
loss is the most frequently recorded symptom. Differences between projects were noted as part 
of the analysis of the frequency of presenting symptoms (section 4.10.5). Thus, 26.9% of patients 
in the South Tees project were recorded as having ‘GP gut feel’ as at least one of their symptoms, 
whereas in Sunderland this was true for only 8.1% of patients. This may be related to the different 
age and socio-economic profiles of the patients registered with participating GP surgeries in each 
of the two projects. However, it may also be that presenting symptoms are not being recorded in 
full at the point of referral. If this trend continues as the projects continue, it is recommended 
that further analysis of presenting symptoms in primary care is considered (see Recommendation 
8 (5.3 Recommendations) and the section on presenting symptoms (section 4.10.5). 
 
4.4 Primary and secondary care feedback on the implementation of VSP 
There have been no significant challenges relating to rolling out the intervention across the three 
pilot areas. The evaluation found that a key issue of concern which project leads have been 
cognisant is the need to avoid what could be described ‘big bang’ approach when implementing 
the VSP across the entirety of the CCG footprint. Instead, programme leaders particularly in 
Newcastle and South Tees, opted to roll out the intervention in a deliberate and staged manner 
on practice-by-practice basis in order to avoid any potential overloading of existing clinical 
resources and staffing capacities. For instance, a senior primary care clinician in Newcastle stated 
that only a small number of practices are involved in the early stages of the pilot to prevent a 
surge of demand in patient numbers that could potentially overwhelm the existing resources of 
secondary care services:  
“… we've got to do that carefully because they [secondary care] don't want 
every practice to start at once … There are going to be two practices to start 
with and hopefully iron out any problems once that starts to work. Also reassure 
secondary care that there are not going to be hundreds of people coming this 
way”. 
In Hambleton, Richmondshire and Whitby CCG, the VSP was also successfully rolled out in a series 
of phases across this geography. A secondary care practitioner explained the thinking behind the 
phased roll out: 
“…we've done a very slow burn with this pilot…don't get me wrong, we're 
covering the entire Hambleton and Whitby patch now, but actually we've done 
that quite slowly really, just to see how many patients come through the doors 
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so as not to overburden the systems. Being mindful that this is a pilot. So, 
actually I think that's worked really well”. 
From the feedback received by the evaluation, this phasing of the roll out process appears to 
have been a successfully approach adopted by the pathway geographies. It has allayed 
operational capacity concerns among secondary care clinicians regarding the potential of the 
intervention to overburden existing administrative systems, clinical services and staff capacities. 
These concerns were primarily focused on the capacity of radiology departments to cope with 
any significant increase in patient referral numbers, especially as it is acknowledged across all 
pathway pilot areas that radiology departments and their personnel are working at virtually full 
capacity (indeed this is a national issue) and therefore there is little slack in the system. A senior 
secondary care clinician in the Newcastle pilot commented:  
“I think we've even got issues with capacity for CT scanners and stuff as well. 
They're being used to the max”. 
However, the evaluation found that radiology departments and their clinicians are willing to take 
on the task within existing capacity and resource constraints.  Indeed, it is fair to say that 
radiology personnel have been receptive and support of the VSP concept:  
“ …there's not been anybody in radiology who has said; no, we're not doing it … 
we'll find a way to make it work” [Newcastle senior secondary care clinician].” 
This highlights the positive relationship between primary and secondary care personnel and a 
willing to work together in order to successfully implement the VSP, across all of the pathway 
geographies. 
 
In addition, project leads also emphasised that this phased process allowed for the identification 
of any potential early teething troubles with the VSP, enabling any fine tuning to take place 
before there was a wider expansion across the CCG footprint. A project leader at the Newcastle 
pilot explained the rationale of this process to the evaluators:  
“…we need to get the first patients through the pathway to just make sure 
there's no little wrinkles or anything that needs to change. Then, I do think that 
they will quite quickly roll out to more practices” 
In this respect, all of the pathways are viewed as an iterative development process by the project 
teams, with experiential learning continuously incorporated into incremental improvements of 
the pathway. 
 
4.5 Primary and secondary care feedback on the performance of the VSP 
The evaluation sought views of primary and secondary clinicians and managers about their 
perceptions of the VSP and its performance to date across the three pilot locations.  
Overall, the evaluation can report the positive finding that the intervention has been well 
received in each pathway area among all clinical groups and professions and the concept 
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underpinning the intervention is widely supported. In particular, the pathway is seen as 
addressing an important gap for those patients who do not easily fit with existing two-week rule 
pathways and reducing the need for multitude of investigations requested by primary care, as a 
lead GP in the South Tees explained: 
“As to what the intervention or pathway is replacing or enhancing, it's enhancing 
all the two-week rule pathways and it's filling the gaps for people who don't fit 
into that but they've got the suspicion that they've got something nasty going 
on. …I suppose the thing it is replacing is lots of the investigations that are being 
done in General Practice. Because everything is being done in the one place, at 
the one time”. 
The VSP also addresses the referral dilemma experienced by GPs who are a struggling to direct 
vague symptoms patients towards appropriate clinical pathways, providing General Practice with 
an additional clinical option: 
“I just think it seems like it's one of those things that as soon as somebody said 
they were going to launch it, we kind of thought: ‘gosh, that's a good idea, that's 
really great.’ So yes, I'm really happy it’s there as part of our clinical arsenal to 
use”. [South Tees General Practitioner]. 
It is clear from the evidence found by this evaluation that among General Practitioners the VSP is 
viewed as a much needed intervention, capable of empowering GPs, especially when they are 
unsure about making a definitive diagnosis. A lead GP in Sunderland stated that:  
“…what we also wanted to do was empower GPs with the diagnostic tools and 
give them a kind of - a tool if you like when they are stuck. Often we are placed as 
clinicians in the conundrum of; we know something is wrong but we don’t know 
where exactly the problem is. That's one of the key outcomes we would expect, 
is to have a clear pathway that would almost be prescriptive of what has to be 
done …when symptoms are vague.” 
To date, there has been positive feedback from primary care about the VSP in Sunderland and 
South Tees where the intervention has been operational for some time. A GP lead in the 
Sunderland pilot, who is in regular communication with a range of colleagues across their CCG 
footprint, provided this insight:  
“… we've had so many GPs compliment us about how helpful they find this to be 
and how much it helps them and their patients as well.” 
Comments like this have been typical of feedback the evaluation team has received. A GP in the 
South Tees area believed that the introduction of the intervention has been a positive 
development, which has benefitted their patients:  
“I think yes, because as good as the templates are for the specific conditions, 
they don't always cover for every patient presentation. So, I think having 
something like that [the VSP] within the system makes a lot of sense…some of 
the things I've had - x-rays - I've been in the dilemma of where do I send this 
patient? Because the presentation wasn't just fitting. ... I buy into it.”  
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One lead GP did raise a cautionary note about the intervention, questioning whether the VSP 
would make a significant overall difference to clinical outcomes for vague symptoms patients as 
a cohort. This was based on a view that the volume of patients referred along the pathway might 
be low, due to a lack of clarity over the definition of vague symptoms:  
“Basically, looking at it from a GP perspective I'm not too sure, I'm not too 
convinced, actually, that a pathway like that might be high demand. These kinds 
of patients with vague symptoms. As I say, it's the definition of what vague is. 
Some GPs don't consider them vague, some people might. My advice was that 
perhaps the numbers going through this pathway would be quite low. But also, 
we … are quite lucky because we do have capability to request things like CT. 
Would they be doing anything different to what we're doing already? I can 
understand the way of streamlining the approach for the patient, but if someone 
comes to see me with vague-ish symptoms, I would expect them to come back 
and see me with the results. That's my own personal opinion on it. I'm not too 
convinced that a pathway like this would make such a massive difference, but I'm 
open to the counterargument towards that, really.” 
A secondary care professional in South Tees, who regularly engages with General Practice, told 
evaluators that they received positive comments from GPs about the intervention:  
“Interestingly, the feedback from GPs is: ‘we've got somewhere to send these 
patients now. We've struggled to know - we've tried to fit them into a two-week 
rule pathway but sometimes they just don't fit.” 
In their responses to the evaluation team, secondary care personnel were equally as 
complimentary about the VSP as their primary care colleagues. In the first instance, it is clear that 
secondary care professionals have been supportive and committed to the pathway, exemplified 
by many clinicians giving their time for free (for a more detailed exposition on this subject, see 
below). A senior secondary care clinician in Sunderland told evaluators that ‘there seems to be a 
lot of interest in it [VSP] within the hospital.’ In the South Tees pilot area, a secondary care 
clinician commented that the secondary care team with operational responsibility for the VSP 
had:  
“… loved being part of the pilot, we've loved doing the pilot. We really do see its 
benefit ... we're probably biased; we think we've got a really good pathway.” 
Whilst noting that there is very limited knowledge of the pathway among secondary care staff 
generally who do not have regular contact with the VSP team or vague symptoms patients, a 
secondary care practitioner in South Tees told evaluators that they had received positive 
feedback from colleagues once they were made aware of the purpose of the pilot: 
“… when you do speak to people about it they think it's great. And the success 
stories that we've had so far have been very positive.” 
Responses from radiology in all pilot geographies have also been positive towards the 
intervention, exemplified by a willingness among personnel in radiology departments to 
undertake the VSP workload, on what has been described as a ‘best efforts’ basis. A senior 
secondary care clinician at the Newcastle pilot commented that:  
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“… there's not been anybody in radiology who has said: ‘no, we're not doing it. 
… We'll find a way to make it work.” 
No testimony was gathered directly from patients about their journey along the pathway as part 
of this evaluation. However, primary and secondary care professionals did provide some 
anecdotal secondary evidence in the form of their perceptions of patient’s experiences of the 
VSP. Significantly, these limited impressions of patient experiences have been positive. For 
instance, a senior secondary care clinician in South Tees stated that they had received positive 
comments from those vague symptoms patients who had been referred to the pathway:  
“You get good feedback from patients because they get seen quickly and sorted 
out.” 
Similarly, primary care clinicians have reported high levels of patient satisfaction. A GP in 
Sunderland stated that they believed patient experiences to date had been positive: 
“They [patients] have felt that their complaints or representations have been 
addressed in the sense that they've had - I mean, a scan is a big deal. I think it's 
been positive in that sense. They can feel that they've had a follow-up check.” 
A GP in South Tees recounted feedback they had received from a patient who had been referred 
to the VSP: 
“…she thought it was amazing. Fortunately, she didn't have cancer but she was 
very, very impressed…” 
Overall, the feedback to date obtained by this evaluation indicates that the vast majority of 
clinicians and professionals who have operational responsibilities for the intervention are 
enthusiastic about the pilot. What is more, some medical professionals, especially in radiology, 
have been proactive in supporting the VSP, often doing so on a goodwill basis. Anecdotal 
evidence from a clinical perspective also tentatively suggests that patients too have had positive 
experiences of the intervention and high levels of satisfaction have been reported.  
 
4.5.1 Challenges 
In each of the pathway areas, there have inevitably been what might be described as teething 
issues, virtually all of which are to be expected when rolling out a project of this nature. From the 
evidence gathered, none of these issues were found to be insurmountable or threatened to 
undermine the process of implementation and the operational efficacy of the intervention.  
A key challenge when attempting to implement the VSP has been the capability of NHS IT 
systems to be adapted to pathway requirements. This issue has been a common issue of concern 
in the three VSP pilots. In Newcastle for example, there has been considerable discussion 
between primary and secondary care about the IT system and cross-sectoral communication 
more generally, given the technical limitations imposed by existing processes, as a senior 
secondary care clinician explains: 
“…it's [about] how GPs and secondary care communicate with each other 
through their IT systems. And how we [secondary care] provide robust feedback 
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[to primary care] and then follow-up information when it comes to booking 
specific slots within the secondary care system.” 
The delay in Newcastle in implementing the VSP was attributed to ensuring that the IT referral 
system could be configured to the requirements of the pathway and would be functional in 
operational circumstances. One of the main practical implementation issues relating to the IT 
system that has provoked significant internal discussions is the need to ensure patients can be 
effectively navigated along the pathway:  
“The problem we had at the last minute - the hospitals were unhappy about their 
internal systems. If a CT scan was found to have a cancer, how were we going to 
ensure that patient got to the right place? They were aware that they had 
different mechanisms for different tumour groups.” [Lead General Practitioner] 
More specifically, as seen from a secondary care perspective, the delay in implementing the 
pathway in Newcastle was: 
“…because it's working out the IT and communication system between primary 
and secondary care. Because the GPs have a certain way of booking patients into 
certain slots and certain requests and things. To do this, the pathway we needed 
to set up something slightly different, so that they weren't double-booking slots, 
and that they were using a specific format for the request … how that is set up 
and what the limitations of that are. But then also about choose and book and 
that system…[and] if we refer somebody onwards in the Trust, how we then get 
a two-week referral to match it up to our cancer target data and make sure the 
patient is still being passed from a cancer diagnosis. That's been the main bulk of 
the delay.” [Senior secondary care clinician] 
In order to ‘stress test’ the capabilities of the new referral system in Newcastle, a number of 
dummy runs or tester appointments have been made: 
“…they [secondary care] were uncomfortable with that because they thought 
things might fall down, which is fair enough. So each of the tumour groups had 
long conversations and they are going to have dummy appointments on the 
computer which the nurse or the Coordinator can book the slot, and the GP can 
add the letter to that place.” [A Lead GP] 
Systemically, it would appear that there is a knowledge gap between different specialties of the 
medical profession about how each side use the ICE (Integrated Clinical Environment) system:  
“A lot of us don't know enough about what the other person does, to know how 
they would use it to make it work at our end. Do you see what I mean? … the GPs 
… they know the front-end of ICE. Our radiologists will know the requesting end 
of ICE, but we don't really understand what each other are doing.” [Senior 
secondary care clinician]. 




“…modifications for ICE so that certain things can be put in and we can capture 
that these patients are on a vague symptoms pathway - because there doesn't 
seem to be even a box to put that in, particularly…” [Senior secondary care 
clinician] 
The functionality of the IT system was also an issue identified in the South Tees locality. Whilst 
noting there had not been any major operational difficulties with VSP there had been technical 
issues related to implementation of the vMDT process of the pathway. A secondary care 
practitioner explained: 
“We struggled in the first instance with the virtual MDT component of it, but 
that was more about process. How do we do it? Working in the NHS our IT 
systems aren't particularly as we would want it…So probably that's the only 
thing that we've struggled with, that concept.” 
This IT issue relating to the vMDT was addressed by some basic but effective improvisation by the 
South Tees project team:  
“We've resorted to a good old-fashioned Word document on a shared drive, 
which actually works very, very well. There wasn't really a lot of information out 
there we could pinch. So we sort of made it up…and actually, probably it does fit 
what we need at the moment.”[Secondary care practitioner]. 
The feedback suggests that this streamlined Word based system is working well, in terms of the 
decision-making process and allowing for a quick turnaround in the reporting of results. 
As mentioned in the earlier sections of this report, at the developmental stage, there was some 
initial concern among project leaders in all pathway areas that the intervention could lead to a 
surge in patient volumes, which possibly could cause an overstretch of resources, especially in 
radiology departments. These concerns have resulted in short operational delays, particularly in 
terms of having sufficient staff capacity in place, as a secondary care practitioner in the South 
Tees pilot explains: 
“It's not been without its teething problems and that's just been from a 
manpower perspective rather than anything else. But we think we are probably 
there now in a lot of respects, but that's taken some time to get off the 
ground…” 
One important operational issue to emerge from the evaluation is that the VSP, to some extent, 
is reliant on the ‘goodwill’ of hospital personnel, as a secondary care practitioner explains: 
“So we run quite a bit on the goodwill of the ambulatory care team who step in. 
Because the clinics run on their department, so they often step in and help out. 
Which moving forward, we need to look at and improve.” 
Furthermore, it is often the case that radiology departments and the clinical staff are supporting 
the VSP on a ‘best efforts’ basis, as the demands of the pathways are technically not built into 
their current job descriptions and planned workloads. A project leader in South Tees explained: 
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“The pathway here works really well. A lot of the consultants support it on a best 
efforts basis…they don’t have any formal job planning for it and we know this is 
a down side to it.” 
Relying on goodwill is potentially problematic as there is acknowledgement across the pathway 
areas that increases in throughputs of patients could place strain on the capacity and resources 
of the system to cope. The potential for overstretch is recognised by personnel in both primary 
and secondary care. One secondary care practitioner in South Tees commented that the: 
“Numbers [of patients] are small though at the moment. I think we have to be 
really mindful that radiology is a really precious resource … In reality, whether 
that would continue as the numbers increase, I don’t know”. 
Sustainability of projects was an issue identified in MDC pilot projects (ACE Programme 2019 c, p. 
4) and it is clear that sustainability could be an issue affecting the successful implementation of 
existing and new projects. The evaluation has not detected any overburdening of existing 
resources because of excessive patient volumes inundating radiology departments across the 
pathway areas. Nevertheless, the possibility of overstretch is clearly an issue, which pathway 
leaders must remain cognisant, particularly as awareness of the intervention in primary care 
grows and the potential for an increase in patient referrals through the system.  
The evaluation also identified some other challenges facing VSP project teams. In the South Tees 
pathway, there had been a relatively low response rate from GPs about their experiences of 
using the intervention to date. Evaluators were informed: 
“We're struggling - we've not had much from GP Practices. The feedback from 
them has been slow, but we can appreciate they're probably not best placed to 
spend the time filling in a questionnaire, as much as we would appreciate 
it…”[Secondary care practitioner] 
This is a topic that may require further work by VSP project teams to ensure that the views of 
General Practice are effectively captured and fed into ongoing pathway development. 
In Sunderland, the need for more effective patient communication has been identified as an area 
that would benefit from further attention, in terms explaining the purpose of the pathway and 
nature of the diagnostic tests patients will receive. Consistency in conveying this message to 
patients is viewed as particularly important, as a senior secondary care clinician explained to 
evaluators: 
“One area around that we need to do more work on. I wouldn’t say it was a 
disaster but I think it could be markedly improved on, is the patient 
communication, about what we communicate to patients about what tests 
they're having had done, to make sure that's consistent. I think although the GPs 
are telling them some information. I can't be sure it's actually consistent who is 
being told what…” 
This pathway area has recognised the need to improve communication with patients, and the 
evaluation team understand that further developmental work is underway to address this issue. 
A secondary care manager at Sunderland outlined the Trust’s agenda to increase the involvement 
of patients in the future design of cancer pathways: 
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“I'm really looking forward to trying to look at the patient side of things and the 
co-design work. I think we need to be including patients, involving patients in any 
redesign work that we do around cancer pathways. It's a very new entity, our 
organisations, at the moment, but I'm hoping that at a point in time, it's just the 
norm that we involve patients in this type of work.” 
These findings suggest that patient communication practices and their inputs into cancer 
pathway design more generally, are streams of work which all VSP project teams may wish to 
explore going forward. 
More time for the projects to mature will allow firmer conclusions to be drawn on the efficacy of 
the VSP and the specific benefits the intervention delivers.   
In the longest running pilots, the responses received revealed a number of benefits of having this 
intervention available to General Practice. In the Sunderland and South Tees areas, which have 
been operational since last year, the prevailing mood among clinicians is positive about progress 
to date and the future trajectory of the VSP. As one lead GP in Sunderland summed up:  
“From a direction of travel point of view I think we are fairly happy with the way 
it's going.” 
In both Sunderland and South Tees, the VSP appears to be operating relatively efficiently. For 
example, the speed and efficiency of the testing and reporting process undertaken by the 
radiology team in South Tees, comparable with other cancer pathways, was highlighted by a 
senior secondary care clinician: 
“I think the radiology seems to be working very well and they seem to get their 
scans either the same day or the next day, and then reported by the same 
radiologists. I think that's quite impressive really. They are almost getting a 
quicker pathway than the two-week wait pathway.” 
In the Sunderland pathway, a senior secondary care manager expressed positive views about the 
performance to the VSP to date: 
“Efficiency? I would say it was quite efficient in terms of doing a CT. I think the 
conversion rate is quite good as well, how many cancers we pick-up”.  
Despite some initial concerns among project leads and clinicians about the potential of the VSP to 
lead to an over-stretch in resources, this does not appear to have transpired. The various 
pathways have been able to operate within the resources allocated, as a result of careful advance 
planning. A secondary care practitioner in South Tees explained: 
“At the moment there isn't (strain on existing systems), because I think we 
planned it quite carefully and we've been very tight with numbers. The triaging 
helps to make sure that we get the right people in the right place. I think that 
would be a very different answer if the numbers had come through more quickly, 
but they've come in a very sort of sensible way. We have on average about two 
or three a week, which is a manageable workload…” 
In the Sunderland pilot, a lead GP stated that the VSP had performed well in relation to detection 
rates, compared with other interventions: 
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“The pick-up rates from my understanding, it's going very well. In fact it is the 
single biggest intervention with such high pick-up rates, from what I can see. This 
is not a detailed analysis or anything, this is just a raw look at the figures, 
obviously. From a pure numbers point of view it looks very promising.” 
Similarly, in South Tees the intervention had been successful in contributing to the detection of 
cancers, as a secondary care practitioner explained to the evaluation team: 
“I think we just believe it's such a good project. And it's actually been really 
valuable and we've obviously found some cancers in there, which is not great for 
the patients, but in reality is what we wanted to do.” 
It was immediately evident from the feedback received that the position of CCC is critical to the 
effective operation of the VSP. Both primary and secondary care personnel recognised the 
importance of the CCC role. A secondary care practitioner informed the evaluation team: 
“I have to say, without our Cancer Care Coordinator in this role, we could not 
have done this pilot, it's as simple as that. She's highly, highly efficient. She has a 
complete grip on the entire patient pathway; who's in, who's out, what the 
patients need, what the patient's don't. Yes, we truly could not have done it 
without the Cancer Care Coordinator. And anybody who tries to do it without 
one, I feel sorry for them…It's been absolutely pivotal and we had a coordinator 
in post the day the pilot started and that was absolutely paramount to the pilot. 
The fact that she's been there right from day one has made the whole process a 
lot simpler…And she's expedited appointments. She's made sure people have 
come. She's got them here, if they can't get into the hospital by organising 
transport, making sure they don't DNA. Just keeping that pathway flowing. 
There's probably nothing she actually physically doesn't do. Including making the 
tea for patients…” 
Project data to date tends to support the importance of the CCC role in avoiding patients failing 
to attend appointments for assessments and/or diagnostic tests (commonly referred to as Did 
Not Attends - DNAs). Thus, the South Tees VSP, which has had a CCC in post from the start of the 
project, has a 1.9% DNA rate. The Sunderland VSP, which at the time of this report has not had a 
CCC in post, has a 5.7% DNA rate (recruitment for a CCC commenced in July 2019). 
As the response of the interviewee above highlights, the CCC requires a broad range of skills and 
personal attributes to perform this multifaceted role. Interestingly, in one pathway location the 
evaluation team were informed that the person recruited to the CCC position came from an 
administrative background and the individual’s interpersonal skills in relation to dealing with 
patients and working along alongside clinicians were deemed a critical attribute essential to this 
specialist role. A secondary care practitioner set out the qualities required for the Coordinator 
position: 
“We went out for more of an administrator. They had to have either something 
like business administration or a health and social care qualification at NVQ level. 
We asked for them to have some knowledge of patient pathways, some 
knowledge of the NHS and actually preferably some previous contact with 
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patients. They didn't necessarily have to be cancer patients, but from a 
vulnerable patient group…” 
The importance of this role to the effective operation of the intervention has also been 
recognised in Sunderland, where the pathway currently does not have this specialist position in 
place. As a result, Sunderland is conducting a recruitment process for the Cancer Care Co-
ordinator role, in order to enhance the operational performance of the VSP in this location. 
There is some evidence from our interviews to indicate that the VSP has reduced the so-called 
‘bounce effect’ undergone by vague symptoms patients who require a number of referrals to 
different clinical specialties/sub-specialties before their condition is diagnosed. Based on their 
experience of using the intervention, a lead GP in Sunderland stated that:  
“It has saved a number of referrals. Normally a patient would be - prior to this 
pathway - I would refer them to a general medical consultant but increasingly 
that is a dying trade, but cardiologists, gastroenterologists, endocrinologists - 
the concept of a general medical consultant is almost non-existent now. So you 
end up with a lot of different consultants before they are diagnosed…”                                                                                         
Overall, the qualitative findings of this evaluation indicate that the VSP has contributed to a 
number of positive outcomes for patients and has provided GPs with an additional weapon in 
their ‘clinical arsenal’ to more speedily address the needs of patients who present with vague 
symptoms.  
 
4.6 Number of referrals and pathway uptake 
A total of 226 patients have been referred to a VSP, during the period of this evaluation5. Data for 
the Sunderland project covers the eighteen month period between 15 September 2017 and 31 
March 2019, with 210 patients being referred to the pilot ’check and book’ service/VSP by 40 GP 
surgeries. The pilot project, where direct access to CT was given for thorax and abdominal 
symptoms, was a precursor to the VSP project that was subsequently subsumed into the NCA 
project as the Sunderland VSP. Since no changes were made to the structure, the data from the 
previous operation of the CT access project has been included by Sunderland as part of their VSP 
project data.  
Data for South Tees CCG covers the nine months between 1 October 2018 and 30 June 2019. 52 
patients were referred to the VSP from 22 GP surgeries, although not all 22 surgeries were 
involved from the beginning of the project.  
In relation to referral numbers, there were no reports from interviewees of any significant 
overstretch of resources in the pilot areas that have been operational for the longest period 
time. In this regard, both Sunderland and South Tees have found patient volumes to be 
manageable, as a secondary care practitioner in South Tees explained:  
                                                             
 
5 The evaluation was conducted between February – August 2019. 
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“At the moment there isn't [any strain on resources], because I think we planned 
it quite carefully and we've been very tight with numbers. The triaging helps to 
make sure that we get the right people in the right place. I think that would be a 
very different answer if the numbers had come through more quickly, but 
they've come in a very sort of sensible way. We have on average about two or 
three a week, which is a manageable workload.” 
Similar feedback was received from Sunderland, where patient numbers have remained relatively 
constant throughout the duration of the pathway and the volumes to date have not exceeded 
original estimates forecast by VSP planners:  
“Well, I think the numbers were about what we thought they might be. Since 
starting in earnest in January 2018, the numbers have been steady and they 
haven't gone up a lot. I think probably our expansion to South Tyneside will 
increase it, because obviously it's a larger trust now…so I think that will expand 
a little bit…” [Senior Secondary Care Clinician]. 
These results are consistent with the findings of the ACE evaluation of MDC pilot projects (ACE 
Programme, 2019c, p. 3), which found that despite concerns about meeting demand for 
additional diagnostic capacity, such as radiology or endoscopy, this had not been an issue for 
projects.  
However, it is important to note that in at least one pathway location there is an occasional 
reliance on ‘goodwill’ from other clinical colleagues to assist with the management of some 
patients. A secondary care practitioner told evaluators:   
“I would say our main issue at the moment is; it's manageable for myself, from 
the perspectives of the clinics. Today, for example, we have a specialist oncology 
nurse who is here to clerk the patient in and take their blood. Then the 
consultant will see them when the blood test results are in and the CT has been 
reported. However, this morning the oncology nurse also covered [another 
hospital] site for acute oncology and she had two poorly patients who she also 
had to see…” 
Again, this was consistent with the results of the ACE evaluation of MDC pilot projects, which 
found that all pilots experienced some pressure relating to securing MDC clinician capacity (ACE 
Programme, 2019c, p.2). 
 
4.7 VSP uptake by GP practices 
Data reporting the uptake of the VSP by GP practices is not presented in this evaluation report, as 
the rollout of uptake in South Tees has been managed specifically to enable implementation to 
be monitored and to manage resource demand. However, it is recommended that uptake by GP 
practices is monitored during the remainder of the project (and reported on in any future reports 
put together by the programme team), to identify whether further promotion of the VSP is 
required to achieve appropriate uptake. Appropriate uptake levels may be evaluated in 
comparison to the guidance for the implementation of RDCs (NHS, 2019, p. 25): 
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“Cancer Alliances should ensure their RDC(s) provide sufficient capacity so, by the end of the first 
year, 20% of cancer patients with non-specific symptoms in their area are diagnosed via an RDC and 
50% of GPs are actively referring into RDCs.” 
 
These diagnosis and uptake rates have been calculated based on high-level modelling for 
potential population coverage for RDCs. This estimates that within any Cancer Alliance area, 
approximately 22% of people currently diagnosed with cancer by any route are diagnosed based 
on vague (or non-specific) symptoms. Based on the 8% conversion rate reported in the ACE MDC 
Programme (Ace Programme, 2019b, p. 13), the RDC Implementation guidance estimates that to 
diagnose 1 person with cancer, 12.5 patients need to be seen. 
 
5.3 Recommendations 1: The NCA monitors uptake of the VSP by GP practices for the 
remainder of the project to identify whether further promotional activity needs to take place 




4.8 Profile of patients and participating GP surgeries 
Profile data related to patients registered with each GP practice may identify trends that merit 
further investigation, for example, differences in access to the VSP. It may also provide 
contextual information to differential performance and outcome data for different projects. 
Therefore, summary data on GP practice size, age and deprivation profiles, ethnic diversity and 
rural-urban location is presented below. 
 
4.8.1 GP practice size 
Nearly half (49%) of GP practices participating in the NCA VSP pilot project to date are medium in 
size (5,000-9,999 patients). A third (32%) are small (less than 5,000 patients) with 17% being large 
(10,000 – 14,999 patients) and 2% having the largest practice lists in the project (more than 15,000 




Figure 2. Proportion of GP practice sizes participating in the NCA VSP pilot projects. 
Over half (55%) of VSP referrals are made by medium size GP practices (Figure 3). Proportionately, 
large GP practices make twice as many VSP referrals as small GP practices, even though small GP 
practices are twice as frequently occurring. The evaluation team is not able to establish an 
explanation for this.   
 
Figure 3. Proportion of VSP referrals by GP practice size. 
In South Tees, over half (54%) of participating GP practices are medium sized (Figure 4), but 
account for 65% of VSP referrals in South Tees (Figure 5). 36% of participating GP practices are 




Figure 4. Proportion of GP practice sizes participating in the South Tees VSP project. 
 
Figure 5. Proportion of VSP referrals by GP practice size in South Tees. 
47% of participating GP practices in the Sunderland VSP are medium sized (Figure 6) and are 
responsible for a similar proportion (51%) of VSP referrals (Figure 7). However, 30% of GP practices 





Figure 6. Proportion of GP practice sizes participating in the Sunderland VSP project. 
 
Figure 7. Proportion of VSP referrals by GP practice size in Sunderland VSP. 
These results suggest an effect of small and large practice size on rate of referrals. Thus, small GP 
practices tend to make up to 50% fewer VSP referrals, proportionate to how often they occur in 
the project. Similarly, large practices tend to make nearly twice as many VSP referrals, 
proportionate to their occurrence frequency. This trend is consistent across both projects, 
despite the differences between GP practices in the two projects (discussed further below but 
relating to the age, deprivation, ethnic and rural-urban profiles of GP practices in the two projects 
to date). Therefore, it is recommended that the trend continue to be monitored throughout the 
rest of the project. If the trend persists, further exploration may provide insights to operational 
aspects of the pathway to maintain equitable access.  
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4.8.2 Relative deprivation 
An estimated measure of the relative deprivation6 (based on the Index Multiple Deprivation, 
IMD) of areas covered by each participating GP practice was obtained from the PHE National 
General Practice Profile website.   
A majority (67%) of participating GP practices were in relatively deprived areas (deprivation 
deciles 1-4). A fifth were in mid-deprivation level areas and 14% were in less deprived areas 
(deprivation deciles 6-9) (Figure 8). 
 
Figure 8. Percentage frequency distribution of participating GP practices by deprivation decile. 
However, the results for each of two operational projects were quite different. The South Tees 
project had deliberately chosen to start the project in rural, less densely populated areas which 
were characterised by older (often retired) and more affluent residents. Thus, 91% of participating 
GP practices in the South Tees VSP were in the least deprived areas (deciles 6-9), with only 5% in 
mid-deprivation areas (decile 5) and 5% in lower deprivation deciles (decile 4) (Figure 9). There 
were no GP practices in the lowest three deprivation deciles (1-3). 
 
                                                             
 
6 The deprivation decile for each GP practice represents the population-weighted average over the IMD scores of the 
Lower Super Output Areas where the practice population lives using 2016 populations. Deprivation scores cover a 
broad range of issues and refers to unmet needs caused by a lack of resources of all kinds, not just financial. 
Deprivation scores are not measures of affluence; all of the indicators used in the index are designed to identify 





Figure 9. Percentage frequency distribution of participating South Tees GP practices by deprivation decile. 
Conversely, 96% of participating GP practices in the Sunderland project were in more deprived 
areas (deciles 1-5) (Figure 10). 
 
Figure 10. Percentage frequency distribution of participating Sunderland GP practices by deprivation decile. 
These trends are likely to change as the projects progress, and particularly as the South Tees 
project is rolled out to more urban areas. Thus, it is recommended trends relating to deprivation 
profiles in participating projects continue to be monitored in relation to equitable access and to 
provide contextual information to differences in outcomes in different areas. 
4.8.3 Ethnic diversity of participating GP practice registered patients 
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Estimates of the ethnicity7 of patients registered with participating GP practices was obtained 
from PHE National General Practice Profile website, an outline of this follows. 
The most frequently occurring (estimated) non-white ethnic group in participating Sunderland GP surgeries was ‘Other 
non-white’ (88% of participating surgeries), together with ‘Asian (70% of participating surgeries ( 
Table 3). 




% of participating GP surgeries 
recording patients in each non-
white ethnic category 
70% 88% 2% 7% 
 
Table 3. Percentage of participating Sunderland GP surgeries with estimates of non-white ethnic groups (source: PHE 
National General Practice Profile). 
The most frequently occurring (estimated) non-white ethnic group in participating South Tees GP surgeries was ‘Other 
non-white’ (86% of participating surgeries), together with ‘Asian (32% of participating surgeries) ( 
Table 4). 




% of participating GP surgeries 
recording patients in each non-
white ethnic category 
32% 86% 9% 5% 
 
Table 4. Percentage of participating South Tees GP surgeries with estimates of non-white ethnic groups (source: PHE 
National General Practice Profile). 
 
4.8.4 Age profile of participating GP practice registered patients 
At this point in the project, half (51%) of participating GP practices in South Tees have patient age 
profiles where a quarter to one third of patients are over 65 years of age (Figure 11). This reflects 
the implementation strategy of the project to target rural, less populated areas which in the 
South Tees area are characterised by high numbers of older (often retired) and more affluent 
populations.  
                                                             
 
7 Estimated proportion of non-white ethnic groups in the practice population (weighted average over the 
contributing LSOAs). Based on data drawn from the 2011 Census using ethnicity categories: 
White; Mixed/Multiple ethnic groups; Asian/Asian British; Black/African/Caribbean/Black British; Other 




Figure 11. Proportion of older patients (>65 years) amongst South Tees GP practices. 
Over half (57%) of participating GP practices in Sunderland have patient age profiles, where the 
proportion of older patients (> 65 years) in the practice list is lower (between 16-20%) (Figure 12). 
 
Figure 12. Proportion of older patients (>65 years) amongst Sunderland GP practices. 
These trends are likely to change as the projects progress, and particularly as the South Tees 
project is rolled out to more urban areas. Thus, it is recommended trends relating to age profiles 
in participating projects continue to be monitored to provide contextual information to 
differences in outcomes in different areas. 
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4.8.5 Rural-urban differences between projects 
Data on the rural-urban location of participating GP practices has not been presented in this 
report. As described above in 4.2.1 South Tees Pathway Design, the rollout of the South Tees 
pathway has initially targeted rural GP practices and the Friarage Hospital, which serves a rural 
population of 122,000 people in its 1,000 square miles area. At the time of this report (August 
2019), more urban areas and the areas served by the James Cook Hospital in Middlesbrough, one 
of Europe’s largest and most modern, had not yet commenced.  Thus, until all GP practices across 
all rural and urban areas in South Tees are participating, this data would be incomplete and not 
helpful.  
However, people living in rural areas are 5% less likely to survive cancer compared to people in 
urban areas, even when key confounders such as socio-economic status are taken into account 
(Carriere et al., 2018, p. 225). For example, one study in North East Scotland found that rural 
patients were diagnosed and treated for their cancer more quickly than people who lived in 
urban areas of the same territory, yet rural dwellers still died earlier (Turner et al., 2017, p. 444).  
Therefore, it is recommended that data on the rural-urban character of participating GP practices 
is and differentials between performance and outcome data are monitored by the programme 
team.   
 
Recommendation 2:  It would be useful for the programme commissioners to continue 
monitoring a number of metrics, to include: trends relating to GP practice size and proportion 
of VSP referrals; trends relating to GP practice size, age, deprivation profiles, ethnic diversity, 
geographic profile, are monitored with regard to equitable access or to provide information on 
performance and outcomes against different variables.  
 
 
4.9 Appropriate use of the pathway 
Project teams in all pathways areas are aware of the potential for inappropriate patient referrals 
by GPs to the VSP. A lead GP in Sunderland cautioned: 
“What we don't want is people using it irrelevantly just because they think that 
there's something wrong, you know? But if there has been too many scans and 
whether there have been too many scans; because now we know that the service 
is available or they are doing too many scans just to be on the safe side. We have 
people almost erring on the side of caution.” 
There is awareness in all pilot areas of the need to monitor inappropriate referrals and to react to 
this if the number of such referrals become too high. In the two more mature pilots areas, 
interviewees did highlighted a number of inappropriate referrals. In one pathway area, a 
secondary care practitioner explained why they thought inappropriate referrals were occurring: 
“I would say it's probably down to them not understanding what we're here for. 
For example, one of the GP Practices that hasn’t engaged as yet, sent one for 
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breast pain; no associated weight loss, no abdominal pain, no previous history, 
nothing.  If [the GP] was concerned about breast cancer then it obviously should 
have just gone straight to breast. So there's been the odd ones like that. We've 
seen a couple of patients who we probably shouldn't have but did, just erring on 
the side of caution.” 
Although, a higher rate of inappropriate referrals may be expected during earlier phases of the 
VSP, as GPs become familiar with the referral criteria, qualitative feedback suggests there are no 
concerns that primary care is using the intervention inappropriately.  
To date, the rate of referral rejections in the South Tees project has been 15.4% (two rejections in 
Q1 (one of these also recorded a new non-cancer diagnosis and was included in that category in 
the project return; one in Q2 and seven in Q3). No referrals in the Sunderland project have been 
declined. The IT system used in Sunderland for the ‘check and book’ service for GPs to request a 
scan, limits GPs to 50 characters. Thus, unlike typical referrals, which consist of a letter from the 
GP, together with a patient history, VSP referrals in the Sunderland project may not provide 
sufficient information to enable secondary care clinicians to reject inappropriate referrals.  
Incorrect use of the pathway is not necessarily unexpected, as GPs get to know of and use the 
pathway. Furthermore, since the pathway is being rolled out in a phased approach in South Tees, 
this period of acclimation might be expected to last until the pathway is fully embedded across 
the project territory. However, it is recommended that referral rejection rates are monitored 
throughout the project in order to identify potential operational issues that need addressing. 
 
Recommendation 3: Referral rejection rates are monitored throughout the project to identify 
whether repeat/revision of guidance on referral criteria or other action is needed. 
 
 
It is also recommended that consideration of how pathway configurations where there is minimal 
referral information/ no clinic assessment can evaluate and monitor inappropriate referral rates. 
It is worth noting that the specification guidance for the implementation of Rapid Diagnostic 
Centres (RDCs) (NHS, 2019) requires all referrals to capture relevant information about the 
patient, in line with the minimum dataset (section 5.3.3) and for all referrals to be reviewed to 
ensure all referral information is present and that RDC is the most appropriate pathway for the 
patient (section 5.4.1). The guidance also requires that where GP ‘gut feeling’ is a reason for 
referral, this needs to be clearly described. Therefore, referrals forms will need to allow space for 
this to be included.  
 
Recommendation 4: VSP configurations where minimal referral information is available and/or 
no clinic assessment is performed, consider how they can how they can obtain sufficient 
referral and patient information in order to evaluate referrals and monitor inappropriate 






In summary, where referrals are reviewed, a rejection rate of 15.4% has been recorded to date. 
There is no significant evidence that referrals are being made inappropriately, although there is 
no evidence that projects are specifically monitoring rejection rates. Therefore, it is 
recommended that referral rejection rates are monitored and that projects with little referral 
information/no clinic assessment consider how inappropriate referrals can be monitored. 
 
4.10 Characteristics of patients referred to the VSP 
Data from both operating pathways about six characteristics of patients referred to the VSP are 




4. Performance status 
5. Presenting symptoms 
6. Duration of symptoms prior to presentation 
 
4.10.1 Gender 
Of the 226 patients referred to the VSP to date, over half (55%) were female and 45% were male 
(Figure 13). No other gender categories were recorded. This is consistent with the gender 
proportion reported in the MDC aggregate project data (ACE Programme, 2019b, p. 13).  
 
Figure 13. Gender proportion of patients referred to both South Tees and Sunderland VSPs. 
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The patient gender proportion in South Tees (Figure 14) was very similar to that in Sunderland 
(Figure 15), with 56% females and 55% females, and 44% and 45% males, respectively. 
      
Figure 14. Gender proportion of patients referred to the South Tees VSP.  
 
 
Figure 15. Gender proportion of patients referred to the Sunderland VSP 
 
4.10.2 Age 
Over half (52%) of all patients referred to the combined VSP projects were aged 70 or over (Figure 
16). There was an age referral criterion of >30 years for the South Tees VSP, whereas the age 




Figure 16. Age distribution of patients referred to both South Tees and Sunderland VSP. 
The age distribution for South Tees (Figure 17) has nearly twice as many patients under 50 years 
of age (12% for South Tees cf. 7% Sunderland ) (Figure 18), despite having a greater than 30 years 
age criterion and the socio-economic profile of South Tees patients being generally older, rural 
and less deprived. 
  






Figure 18. Age distribution of patients referred to the Sunderland VSP. 
However, the total number of patients for South Tees to date is much lower than that for 
Sunderland8, together with project duration and number of participating GP surgeries and this 
difference may change/disappear as the project continues. Nevertheless, this is a somewhat 
unexpected difference, since one might expect a greater number of patients <50 years in the 
Sunderland VSP, since they do not have a >30 years age criteria and the age profile of Sunderland 
GP practices is younger than that in South Tees. Therefore, it is recommended that this difference 
in patient age distribution frequency is monitored throughout the rest of the project, to enable 
investigation of underlying causes if the trend continues. 
 
Recommendation 5: The age distribution, and particularly the frequency of patients <50 years 




Previous pilot studies of VSPs reported that patients presenting with vague symptoms to their GP 
(and particularly those with weight loss and fatigue) were often from older age groups, who 
therefore also tended to present with comorbidities (ACE Programme, 2017, p. 8). This has 
implications for both the expected outcomes and staging profile of cancers diagnosed as a result 
of referral to the VSP. For example, the death of patients referred to VSP may be associated with 
their co-morbid conditions and the staging of cancers diagnosed for acutely ill patients is likely to 
be at a later stage, due to masking of symptoms by existing co-morbid conditions. Therefore, if 
                                                             
 
8 6 patients < 50 years were referred to VSP in South Tees over nine months cf. to 15 patients <50 years 
referred to VSP in Sunderland over eighteen months 
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patients referred to the VSP show higher levels of co-morbidity this is unlikely to lead to 
improvements in diagnosis at earlier stages. 
There is currently no co-morbidity data available for the Sunderland VSP, since there is no clinic 
assessment and only very limited information in the Sunderland patient referral form. Moreover, 
since patients remain the responsibility of primary care, until and unless abnormalities are found 
and they are referred to the appropriate specialist or pathway, patient information is located in 
primary care systems and may not be immediately available to secondary care. 
However, data is available for most patients referred to the South Tees VSP (45 of 52 patients 
including patients with no co-morbidities and 5 patients for whom co-morbidities are not known). 
This data shows that 40% of patients referred to the South Tees VSP had mild co-morbidity (1-2 co-
morbid conditions) and 35% had moderate co-morbidity (3-4 conditions) (Figure 19). This is 
consistent with data from the MDC programme that reported 43% mild co-morbidity and 27% 
moderate and severe co-morbidity (ACE Programme, 2019b). 
 
Figure 19. Co-morbidity profile of patients referred to the South Tees VSP. 
The South Tees returns include data on the type of co-morbid condition(s), although the return 
only requests information on the top three co-morbidities. The three most frequently occurring 
co-morbid conditions were hypertension (10%), followed by diabetes (9%) - two Type I and six 
Type II diabetes (including two where type not specified but assumed to be Type II) and 
hypothyroidism (6%).  The percentage frequency of occurrence for each co-morbid condition 










% frequency of 
occurrence 
Co-morbid condition(s) (patients may have more than one) 
10% Hypertension 
9% 
Diabetes   
6 x Type II (including 2 cases where type not specified); 2 x Type 1 
6% Hypothyroidism (including sub-clinical) 
5% Previous breast cancer 
5% Coronary (Ischaemic) Heart Disease 
5% Chronic obstructive pulmonary disease (COPD) 
3% Atrial fibrillation 
3% Diverticulitis 
3% Ex- or current smoker 
2% Anaemia 
2% (Congestive) heart Failure 
2% Chronic Kidney Disease Stage G3 
2% Pneumonia 
1% Addison’s disease 
1% Anxiety 
1% Aortic stenosis 
1% Back pain 
1% Cerebrovascular accident 
1% Chest infection 
1% Cholecystitis 
1% Chronic kidney disease  
1% Chronic sinusitis 
1% Colitis 
1% Constant nausea 
1% Depression 
1% Ear pain 
1% Gastric ulcers 
1% Gout 
1% Haemochromatosis 
1% Hip replacement  
1% Hysterectomy 
1% Immune thrombocytopenia purpura 
1% Laminectomy 
1% Melanoma 
1% Monoclonal gammopathy of unknown significance (MGUS) 
1% Myocardial infarction 
1% Osteoarthritis  of knee 





1% Polymyalgia rheumatica  
1% Previous pulmonary embolus 
1% Renal failure 
1% Rheumatoid arthritis 
1% Sciatica 
1% Seborrheic keratosis 
1% Syncope 
1% Tachycardia  
1% Vascular dementia 
1% Weight loss 
100%  
 
Table 5. Percentage frequency occurrence of recorded co-morbid conditions in patients referred to South Tees VSP 
(patients may have more than one). 
Further information on co-morbidities for patients referred to the South Tees VSP, together with 
associated diagnosis outcomes, grouped into cancer and non-cancer diagnoses is provided in 
Error! Reference source not found.). 
 
Recommendation 6: The Project Steering Group considers whether co-morbidity data for all 
patients on the VSP is essential for interpreting project results and, if so, discuss with projects 
whether and how this data can be accessed and extracted.   
 
 
4.10.4 Performance status 
Performance status also has a highly significant effect on patient outcomes (more so than 
patient’s age at diagnosis) (e.g. West and Jin, 2015) and inclusion of this data in the analysis of 
patient treatment options and outcomes may add important contextual information to VSP 
performance data. The implications of poorer patient performance status (which may also be 
associated with co-morbidities) is that this may limit patient treatment options and affect 
outcomes. Thus, even if earlier and faster diagnosis occurs, this may not be reflected in outcome 
data.  It is worth noting that treatment options for patients with better performance status at 
diagnosis can include more aggressive treatments with higher rates of success (and indeed side 
effects), thus this is a somewhat nuanced aspect of VSP outcomes. Performance status is 
routinely recorded as part of patient assessment and treatment decision-making in secondary 
care, although it is not necessarily assessed or recorded as part of primary care data.   
No performance data is currently available on the performance status of patients referred to the 
Sunderland VSP. This is because performance status is assessed once patients are referred from 
primary care into secondary care i.e. only patients for whom the CT scans and blood tests show 
an abnormality and who are referred to a speciality or 2WW pathway. Performance status is 




Recommendation 7: The Project Steering Group considers whether performance status data is 
essential for interpreting project results and, if so, discuss with projects whether and how this 
data can be accessed and extracted.   
 
 
4.10.5 Presenting symptoms 
Currently, data on how many and which symptoms each patient presented with at the point of 
referral is available from South Tees. This shows that nearly half (42%) of patients presented with 
one symptom, over a third (35%) presented with two, with 17% presenting with three symptoms 
and 6% presenting with four symptoms (Figure 20).  
 
Figure 20. Number of presenting symptoms at referral for patients referred to the South Tees VSP. 
For those patients diagnosed with either a cancer or non-cancer condition, nearly half (46%) 
presented with 2 symptoms, a further third (31%) with 1 symptom, 8% with 3 symptoms and 15% 
with 4 symptoms (Figure 21. Percentage frequency of number of symptoms in referrals to the 




Figure 21. Percentage frequency of number of symptoms in referrals to the South Tees VSP that were subsequently 
diagnosed with either a cancer or non-cancer condition. 
Furthermore, whilst absolute numbers of cancer diagnoses are still very low and therefore 
subject to distortion, results to date show that of patients diagnosed with cancer as a result of 
referral to the South Tees VSP,  over half (60%) presented with 2 symptoms and a fifth  (20%) 
presented with either one symptom or three symptoms) (Figure 22).  
 
Figure 22. Percentage frequency of number of symptoms amongst patients diagnosed with cancer in the South Tees VSP. 
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Likewise, numbers may be too low and subject to distortion to identify trends but currently 38% 
of patients subsequently diagnosed with a non-cancer condition presented with only 1 symptom, 
a further 38% with 2 symptoms and 25% with 4 symptoms (Figure 23). 
 
Figure 23. Percentage frequency of symptom number(s) in patients diagnosed with a non-cancer condition in South Tees 
VSP. 
Significantly, more patients (61.5%) presented with weight loss as at least one of their symptoms, 
than any other symptom (Figure 24).  One fifth of patients presented with fatigue (20.6%) and/or 
abdominal pain (19.1%), 14.5% with nausea/appetite loss, 12.2% with a respiratory problem (patients 
could have more than one symptom, therefore percentage frequencies sum to more than 100%). 
According to data collected to date, only 11.8% of patients presented at referral with GP ‘gut’ 
feeling as a symptom, despite this being a requisite in South Tees’ original referral criteria and 




Figure 24. Percentage frequency of presenting symptom type at referral amongst patients referred to the combined VSP 
projects. Patients may have more than one symptom, chart shows prevalence of any one symptom in all patients. 
However, at this point in the project, there is some difference between patients in the two 
projects. Thus, for Sunderland patients, more patients (64.8%) present with weight loss as the, or 
one of, their symptoms, than any other symptom (Figure 25). 
 
Figure 25. Percentage frequency of presenting symptom type at referral amongst patients referred to the Sunderland VSP. 
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In South Tees, weight loss is still the dominant symptom for most patients (48.1%) but more 
patients present with fatigue (32.7%), abdominal pain (28.8%) and GP gut feeling (26.9%) than in 
Sunderland (Figure 26).  
 
Figure 26. Percentage frequency of presenting symptom type at referral amongst patients referred to the South Tees VSP. 
It is noticeable that GP gut feeling is a symptom for 26.9% of patients in South Tees, whereas only 
8.1% of patients in Sunderland are recorded as having GP gut feeling as a referral symptom. The 
profile of patients registered with participating GP surgeries in the South Tees project tends to be 
older, rural and less socially deprived than those in participating GP surgeries in the Sunderland 
project (see Section 4.6 4.7 VSP uptake by GP practices for further details). If this trend 
continues, it may be worth further investigation, and with reference to the body of research on 
the factors affecting GP suspicion of cancer. For example, one study found that GPs first 
impressions about cancer risk are influenced by patient age, gender and ethnicity as well their 
prior experience and knowledge of cancer epidemiology but that GPs were significantly more 
likely to suspect cancer in older patients, irrespective of gender and ethnicity (Adam et al., 2017, 
p. 9). This study focused only on first impressions (using fast-thinking cognitive processes) and 
GPs take other information and use reflective, slow-thinking processes to make reasoned 
decisions about diagnostic possibilities (e.g. see Foot et al, 2011, p. 11 for a model of diagnostic 
strategies in primary care). However, it does highlight the potential range of influences on the 
processes and information that constitute GP ‘gut’ feel and how these might affect referral rates 
in different areas (on top of factors influencing cancer rates in different areas). 
These trends may change as the project continues and more data is gathered, but it is 
recommended that the percentage frequency of patients with specific symptoms continues to be 
monitored for projects separately, as well as together, and that further investigation of 
significant variations, for example, percentage frequency of patients with GP gut feel as a 




Recommendation 8: The project(s) continue to monitor and investigate trends and variations 
in the percentage of patients presenting with each symptom type (and particularly GP gut feel) 
and reports this data on an individual project level as well as combined data for all VSPs.  
 
 
Data showing presenting symptoms with subsequent cancer and non-cancer outcomes is 







Cancer 3 Abdominal pain, weight loss, 
fatigue 
 
C61 Malignant neoplasm of 
prostate 
 2 Abdominal pain, weight loss 
 
C45.1 Peritoneal mesothelioma 
 
 2 Fatigue, general condition 
 
C22.0 Liver cell carcinoma, 9680/3 
Diffuse large B-cell lymphoma 
(DLBCL) 
 
 2 Weight loss, fatigue 
 
C85.90 Non Hodgkin Lymphoma 
 
 1 Weight loss 
 
C78.00 Lung Cancer 
 




 2 GP gut feel, general condition M35.3 Polymyalgia rheumatica 
 
 2 Weight loss, GP gut feel M35.3  Polymyalgia rheumatica 
 




 4 Fatigue, GP gut feeling, 
general condition, Other (sinus 
tachycardia) 
K86.2 Pancreatic cysts 
 
 4 Weight loss, nausea / appetite 
loss, fatigue, other (erythema 
nodosum) 
D82.3 Glandular fever 
 
 2 Fatigue, GP gut feel J06.9 Viral upper respiratory tract 
infection 
 
 1 GP gut feel 
 
A49.9 Bacterial infection, 
unspecified 





4.10.6 Duration of symptoms prior to presentation 
To date, nearly half (43%) of patients referred to the VSP reported that they had been 
experiencing their symptoms for between 3 and 6 months (Figure 27). This is consistent with 
most frequent duration of 3-6 months reported by 56% of patients in the combined MDC, 
although the percentage in the MDC pilot is somewhat higher.  However, figure for this project 
may change as the projects continue. 
 
Figure 27. Percentage frequency of reported duration of symptoms prior to referral to VSP for both South Tees and 
Sunderland projects. 
There is currently a difference between the South Tees and Sunderland projects (Figure 28) and 
(Figure 29) respectively. Thus, the largest proportion (33%) of patients so far in the South Tees 
VSP report having their symptoms for between 5 and 12 weeks, whereas in Sunderland over half 
(57%) of patients report experiencing their symptoms for longer (between 3 and 6 months) 




Figure 28. Percentage frequency of reported duration of symptoms prior to referral to South Tees VSP. 
 
Figure 29. Percentage frequency of reported duration of symptoms prior to referral to Sunderland VSP. 
This suggest that patients in South Tees, who tend to be older, less socio-economically deprived 
than those in Sunderland tend to consult their GP (or be able to consult their GP) more quickly 
than patients in Sunderland. If this trend continues throughout the project, this may be an area 
for further research to explore underlying causes. 
 
4.9 Diagnostic tests 
Most patients (88.5%) to date have had a CT scan of the chest, abdomen and pelvis (Figure 30) 
(patients can have more than one type of diagnostic test therefore percentage frequencies sum 




Figure 30. Percentage of all patients (excluding DNAs) who had each type of diagnostic test (combined VSP data). 
However, it is probably more informative to consider data from the two projects separately, 
given the effect of pathway design on the types of diagnostic tests performed. 
The pathway design of Sunderland VSP means that all patients who are referred receive initial 
screening blood and urine tests, requested and reviewed within primary care. Currently, the 
project does not have access to diagnostic tests performed in primary care and therefore these 
are not recorded in data returns. Where any abnormal or concerning results are identified by the 
GP, patients are referred for a CT scan that includes the chest, abdomen and pelvis via a ‘check 
and book’ service. All referrals are accepted by the Radiology Department, therefore, 100% of 
patients referred to radiology have already had blood and urine tests performed and have been 
referred for a CT scan of the chest, abdomen and pelvis. However, there were eight DNAs during 
the period of the project to date. Therefore, 202 patients referred to the Sunderland VSP had 202 
diagnostic tests, giving an average of one diagnostic test per patients (excluding DNAs) which 
was a CT scan of the chest, abdomen and pelvis. 
The design of the South Tees VSP means that assessment of patients begins with a first screening 
of bloods, carried out in primary care. Patients with abnormal results and whose symptoms meet 
VSP criteria are then assessed in a VSP clinic (located in Ambulatory Care) where a full 
examination of the patient is undertaken and their clinical history assessed. Following this initial 
consultation, a consultant decides the next steps which can include undertaking a second level 
screening of bloods, a CT scan (Chest, Abdomen and Pelvis), Endoscopy or Haematology (or 
other) referral. 
Data relating to the proportion of patients receiving each type of test (Figure 31) was extracted 
from South Tees’ data returns. This shows that most (83%) patients receive blood tests 1 and 2 
and over half (58%) receive a CT scan which covers the chest, abdomen and pelvis. 13% of patients 
received a colonoscopy (with or without a biopsy). 10% a biopsy, and 8% a chest x-ray, endoscopy 
(with or without biopsy) and/or other imaging tests.  6% of patients received an ultrasound (with 
or without biopsy), 4% a PET CT scan, colon CT scan, blood test 3 and/or Other tests (no details 




Figure 31. Proportion of patients receiving each type of test in the South Tees VSP (patients may receive more than one 
type of test, therefore frequencies sum to >100%). 
In total, 213 diagnostic tests have been carried out for 52 patients to date, giving an average 
number of 4.1 diagnostic tests per patient. (There was one DNA in South Tees but the patient 
subsequently attended for diagnostic tests therefore all patients are included in this metric for 
South Tees). 
Comparative data from previous MDC projects (ACE Programme, 2019d) suggests that more tests 
per patient are performed on the South Tees VSP and fewer in the Sunderland VSP (Table 7) but 
this is also affected by differences in pathway design.  
 
 
Leeds Airedale Oldham Wythenshawe BRUHT S Tees Sunderland 
Average number 
of  diagnostic tests 
per patient 
1.5 2.35 1.8 2 1.6 4.1 1 
n= 35 61 38 46 31 52 202 
 
Table 7. Comparative data on frequency of diagnostic test type and average number of tests per patient (source for 
comparative data ACE Programme, 2019c). 
The data on diagnostic tests is presented here for information but it is anticipated this data will 
be used in the cost-effectiveness evaluation of the VSP, when this is performed. It is expected 
that guidance on the methodology for cost-effectiveness evaluation will be available from the 
ACE team in 2019/2020 (ACE Programme, 2019d, p. 7). 
4.10 Diagnosis outcomes 
The conversion Rate (CR), which is the proportion of VSP referrals resulting in a cancer diagnosis, 
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for the project to date is 10.3% (combined data). This is consistent with of the range of individual 
MDC project levels CRs of 4-11% and higher than the 8% CR at MDC programme (ACE Programme, 
2019b, p. 13) (Figure 32).  
A fifth of patients (21.4%) were diagnosed with a new non-cancer condition, which is lower than 
the rate reported for the MDC programme where one third of cases were diagnosed with a non-
cancer condition (ACE Programme, 2019b, p. 14). 
Over half (55.3%) of patients were discharged as ‘all test normal’ and 9.2% pf patients were either 
still undergoing ongoing tests or were still on the pathway. 3.4% of referrals were rejected and 
0.4% diagnosed a recurrence of cancer. 
The VSP combined project CR of 10.3% exceeds the CR for all 2WW pathways for the five years 
2013/14 - 2017/18 in Sunderland CCG (7.4 %;) Hambledon, Richmond and North Yorkshire CCG 
(9.8%) (all of the participating GP surgeries in the South Tees project to date are part of this CCG) 
and England (8%) (2WW Referrals, Cancer Services, PHE).  
Some of the participating surgeries in Sunderland are part of the Durham Dales, Easington and 
Sedgefield CCG, which has a CR for all 2WW pathways of 8.6% for the five years 2013/14 -2017/18.  
 
 
Figure 32. Diagnosis outcomes for patients referred to VSP (combined data). 
The conversion rate for South Tees VSP to date is 9.6%. However, a substantial (30.8%) group of 
patients are either receiving ongoing tests (or still on the pathway for some other unspecified 
reason) (Figure 33). At this point in the project, there is a comparatively low proportion (19.2%) of 
patients discharged with ‘all tests normal’ (compared to 64.3% in the Sunderland VSP but as more 
of the patients still undergoing ongoing tests/still on the pathway are diagnosed, these figures 
may change.  The diagnosis rate for new non-cancer conditions is also comparatively lower 
(23.1%) compared to the MDC findings (one third of cases) (ACE Programme, 2019b, p. 14) but 
consistent with that observed to date in the Sunderland VSP (21.1%). Referrals that were rejected 
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(17.3%) included information about the reasons for rejection for three of the rejections (met 
criteria for Upper GI 2WW pathway). 
 
Figure 33. Diagnosis outcomes for South Tees VSP. 
The conversion rate for Sunderland VSP is 10.5%, which is at the top end of the range of CRs 
reported in the MDC programme (4-11%) (ACE Programme, 2019b, p. 13) (Figure 34). Just over a 
fifth of patients (21%) were diagnosed with a new non-cancer condition, which is lower than the 
rate reported for the MDC programme where one third of cases were diagnosed with a non-
cancer condition (ACE Programme, 2019a, p. 14). A substantial majority of patients referred to the 
Sunderland VSP (64.3%) were discharged after all tests came back normal. Only 3.8% of patients 
are still undergoing ongoing tests or still on the pathway for some unspecified reason. Cancer 




Figure 34. Diagnosis outcomes for Sunderland VSP. 
73 
 
In order to assess the sensitivity of the pathway, it is suggested that the project considers 
whether the calculation of the Detection Rate (DR) (the proportion of cancers treated which 
were VSP referrals) when cancer rates for the surgeries involved and for the periods concerned 
are available. This is consistent with the advice for the implementation of RDCs (NHS, 2019, p. 25), 
which advises that: 
“Cancer Alliances should ensure their RDC(s) provide sufficient capacity so, by the end of the 
first year, 20% of cancer patients with non-specific symptoms in their area are diagnosed via 
an RDC”. 
 
Recommendation 9: The Project Steering Group considers whether the Detection Rate of the 
pathway should be monitored and if they wish to disseminate that information further.   
 
 
4.11 Types of cancer diagnosed 
Of the 27 new cancers diagnosed to date as a result of referral to VSP, 14.3% were lung cancer, 
10.7 % were haematological cancer and 9% were prostate, colorectal or pancreatic cancer (Figure 
35). 3.6% of other types of cancers was recorded: hepatocellular, angiosarcoma, gallbladder, 
renal, stomach, breast, oesophageal, bladder, liver cell carcinoma, Non-Hodgkin’s Lymphoma, 
lung cancer and peritoneal mesothelioma. One case of recurrent cancer (residual CLL) was also 
recorded. ICD10 codes were recorded for all but five cancers in the Quarter 2 return from 
Sunderland (one of these was recorded as lung cancer and has been included in C34,however, 




Figure 35. Frequency of cancer types diagnosed by VSP (combined data). 
 
4.11.1 Common, rare and less common cancers diagnosed 
The four cancers with the highest incidence rate (breast, colorectal, lung and prostate) are 
generally known as the ‘common’ or Big Four cancers. ‘Less common’ cancers are those with an 
incidence greater than 6 per 100,000 population and ‘rare’ cancers are those with an incidence of 
less than 6 per 100,000 population (PHE and Cancer 52, 2015, p. 7). 
Of the cancers diagnosed by the VSP to date (combined data), 53.6% were Less Common and 
14.4% were Rare, which is the category of cancers often diagnosed at a late stage e.g. pancreatic 
or stomach cancer (ACE Programme, 2019b, p.13). Together, this means that 68% of cancers 
diagnosed by the VSP projects to date have been Less Common or Rare cancers, which is 
somewhat higher than the 56% of Less Common or Rare cancers diagnosed by the MDC 
programme (ACE Programme, 2019b, p. 13).  
Data relating to the national and local incidence of the types of cancers found as a result of 
referral to the VSP (Table 8) provides context to the frequencies of cancers diagnosed to date in 








Cancer group or site name ICD10 
code 
European Age-Standardised (AS) Incidence 
Rates per 100,000 Population, England, 
2016 
(persons unless gender stated in cancer group name) 










South Tees CCG 
2014 






Common* Prostate (male) C61 173.7 142.31  180.55 
Breast (female) C50 167.9 189.11  178.15 
Lung C33-34 76.1 118.23  58.58 





C82-C86 23.5    
Pancreas C25 16.7    
Bladder C67 16.7    
Oesophageal C15 14.9    
Cancer of unknown primary C77-C80 14.4    
Stomach C16 10.5    











Mesothelioma  C45 4.5    
Gallbladder C23 1.8    
Recurrent / residual Chronic 
Lymphocytic Leukemia 
C91.1 1.7    
Soft tissue sarcoma (including 
Angiosarcoma) 
C22     
Renal D41.1     
Neoplasm - Secondary 
malignant neoplasm of 
unspecified lung 
C78.00     
 
Table 8. National and local incidence rates for types of cancers diagnosed during the VSP project.
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4.12 Staging of cancers diagnosed 
A major objective for VSP projects is to improve the diagnosis of cancers at earlier stages of 
cancer and improve treatment options and outcomes and patient experiences (ACE Programme, 
2017, p. 1). The symptoms of some cancers, for example, melanoma, breast, mean they are 
easier to suspect than others and these cancers are therefore more likely to be diagnosed 
earlier and more quickly (ACE Programme, 2017, p. ii). Harder to suspect cancers such as 
myeloma, pancreatic, stomach, and lung cancers typically present with vague symptoms and 
are thus less likely to be suspected, take longer to diagnose, be diagnosed at a later stage 
and have poorer outcomes and patient experiences (ACE Programme, 2017, p. ii). For 
example, 67% of people with vague symptoms typically present with late stage cancers 
compared to 45% of people with site-specific symptoms (NHS, 2019, p. 9). 
Of cancers diagnosed to date by the VSP to date, 82% have staging information (cf. to 79% of 
cancers diagnosed in the MDC programme (ACE Programme, 2019b, p. 15). To date, all staging 
information is from the Sunderland project. Five cancers have been diagnosed by the South Tees 
project, all occurring in the most recent quarter (April-June 2019) and staging information is not 
yet available for this quarter. 
Where staging data was available, 35% of cancers were diagnosed at Stage 1, 9% at Stage 2, 9% at 
Stage 3 and 48% at Stage 4 (Table 9). Overall, 44% of cancers were diagnosed at early stage 
(stages 1 or 2), compared to 26% in the MDC programme (ACE Programme, 2019b, p. 15).  
 









Stage 1 30.43% 4.35% 35% 
Stage 2 8.7% 0% 9% 
sub-total 39.13 4.35% 44% 
Stage 3 8.7% 0% 9% 
Stage 4 39.13 8.7% 48% 
Total   100% 
 
Table 9. Staging of cancers diagnosed in the VSP to date (currently staging data available only for Sunderland VSP). 
It is not possible to determine from the summary data returns, to which cancers the staging 
information relates. It is recommended that the Project Steering Group considers whether this 
data can, and should be, extracted from project records for previous reporting periods and also 
that the data return form is amended to enable capture of this information for future reporting 
periods. 
Recommendation 10: The Project Steering Group considers whether staging information linked 
to the type of cancer should, and can be, provided by projects. If so, projects should be asked 
for staging information, linked to type of cancers for previous data returns. Furthermore, the 
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4.13 Non-cancer diagnoses 
The combined project data shows that 20.6% of patients referred to the VSP were diagnosed with a 
non-cancer condition (Table 10).  
 





44 10 54 
Number of patients 210 52 262 
% non-cancer 
diagnoses 
20.9% 19.2% 20.6% 
 
Table 10. Percentage of patients referred to the VSP diagnosed with a new non-cancer condition. 
This is somewhat lower than the programme level rate for the MDC project for the same pathway 
(non-specific but concerning symptoms); where over a third of cases resulted in a non-cancer 
condition diagnosis (ACE Programme, 2019b, p. 14). 
The relative proportion of non-cancer condition categories is shown in Table 11, with further 
details of non-cancer condition types and frequencies provided in Error! Reference source not f
ound.. Diseases of the digestive system were diagnosed in 31.4% (39% in the MDC project, ACE 
Programme, 2019b, p. 14) of non-cancer diagnoses and diseases of the respiratory system in 19.6% 
of non-cancer diagnoses. These two categories accounted for over half of all non-cancer 
diagnoses. 
ICD disease category and code % Frequency 
Diseases of the digestive system K00-K95 31.4% 
Diseases of the respiratory system J00-J99 19.6% 
Neoplasms C00-D49 9.8% 
Diseases of the genito-urinary system N00-N99 9.8% 
Certain infectious and other parasitic diseases A00-B99 7.8% 
Diseases of the circulatory system I00-I99 7.8% 
Endocrine, nutritional and metabolic diseases E00-E89 3.9% 
Injury, poisoning and certain other consequences of external causes S00-T88 3.9% 
Diseases of the blood and blood-forming organs and certain disorders involving the 
immune mechanism D50-D89 
2.0% 
Diseases of the musculoskeletal system and connective tissue M00-M99 2.0% 







Table 11. Relative percentage frequency of non-cancer conditions diagnosed by the VSP (combined data). 
 
4.14 Time to diagnosis 
Currently, two data items relating to time to diagnosis are captured in the summary data returns 
from projects:  








Q1 Q2 Q3 Q1 Q2 Q3 
Median number of days to 
first diagnostic test 
 
13 14 - 2.5 7 7 
 
Table 12. Median days from referral to first diagnostic test. 
Additional data on time to diagnosis is currently available from South Tees detailed project 
records as follows (shown with comparative data from MDC programme level results (ACE 
Programme, 2019b, p. 15) (Table 13). 
 South Tees 
Median (range) days 
n=number of cases 
MDC 
Median (range) days 
n=number of cases 
GP referral to first seen 7 (0-19) 8 (0-84) 
GP referral to cancer 
diagnosis (Cancer diagnosis 
interval) 
24 (13-59) 19 (0-199) 
 
GP referral to New non-
cancer diagnosis 
31 (8-51)  
GP referral to All tests normal 11 (9-28) 
 
 
GP referral to any diagnosis 
(Diagnostic interval) 
24 (8-51)  




Table 13. Time to diagnosis metrics for South Tees (with comparative data from MDC programme level results (ACE 
Programme, 2019b). 
Thus, the South Tees VSP currently has a shorter referral interval (7 days) than the MDC 
programme (8 days) and a much smaller range. The median cancer diagnostic interval (GP 
79 
 
referral to cancer diagnosis) in South Tees is longer (24 days cf. to 19 days) but the range is much 
smaller. 
There are some data items not currently collected in the summary data return including: 
 Date of referral to VSP  
 Date of first seen in secondary care 
 Date of clinical diagnosis 
 Date of start of treatment 
 
Recommendation 11: The Project Steering Group considers whether projects need to provide 
additional data to calculate the full range of metrics and, if so, to amend the data return form 
to collect this data. 
 
 
2. Number of Diagnoses communicated within 28 Days  
The Faster Diagnosis Standard (FDS) has been developed in response to Cancer Taskforce 
recommendations and “will ensure that all patients who are referred for the investigation of 
suspected cancer find out, within 28 days, if they do or do not have a cancer diagnosis” 
(https://www.england.nhs.uk/cancer/early-diagnosis/#faster). Trusts are due to start being 
measured against the FDS from April 2020. 
Currently, Sunderland data shows that 22 of their 67 diagnoses meet the FDS standard (32.8% 
compliance). South Tees FDS data in submitted returns needs correcting but the project reports 
71% compliance with the FDS standard, as at 9 August 2019. 
 
4.15 Treatment 
The data return form does not currently ask for any data relating to treatment and therefore no 
data on treatment has yet been submitted by projects. 
 
Recommendation 12: The Project Steering Group considers whether treatment information is 
required. If so, projects could be asked to provide treatment information relating to cancers 
diagnosed and reported to date, and the data return form amended to collect this data. It is 
suggested that any amendment to the data collection form enables the type of cancer, staging 





4.16 Data collection 
Some missing/unavailable data items and minor data entry errors were identified in quarterly 
returns during the period of this evaluation. Discussions with the project teams and NCA quickly 
corrected small data entry errors (which could nevertheless have had significant distorting 
effects due to the small numbers involved, for example, numbers of cancers diagnosed. 
However, there is currently no data quality assurance process to identify, correct and audit data 
corrections or changes and this may be something the project needs to develop and implement 
for the remainder of the project. 
 
Recommendation 13: The Project Steering Group considers whether the VSP project needs to 
develop and implement a data quality assurance process to identify, correct and provide an 







5 Discussion, conclusion and recommendations 
 
The data gathered, collated and analysed in pursuit of this evaluation and report highlights a 
range of programme and project successes, as has been detailed above. Some of these are 
summarised below.  
Nevertheless, the possibility of overstretch is clearly an issue, which pathway leaders must 
remain cognisant, particularly as awareness of the intervention in primary care grows and the 
potential for an increase in patient referrals through the system. 
 
5.1 The three pathways 
5.1.1 Implementation 
The evaluation evidences that clinicians and professionals involved in the implementation of the 
projects are enthusiastic about the pathways and the ongoing potential of the pathways. 
Furthermore, the data sets out the pro-active approach being taken by many involved in the 
programme. There was some initial fear that the pathway creation could overload key areas of 
activities, particularly radiology; it appears that this concern has not been realised, however, 
pathway leaders should remain cognisant of that risk as patient referrals increase. 
 
5.1.2 Performance 
The intervention has been well received and the underpinning concept widely acknowledged and 
supported. It is considered that the pathway successfully addresses a gap for particular patients 
who would not fit with the two-week rule. Additionally, it is believed that the pathway also 
reduces the need for, and the provision of, multiple investigations. Importantly, staff interviewed 
as part of the evaluation shared anecdotal observations strongly suggesting that some patients 
are benefitting from the pathways and are finding the experiences positive.  
 
5.1.3 Pathways in Action 
The pathways, from going live, had seen over 200 referrals at the time of this evaluation. 
Evidence shows that the pathways are being utilised in the way intended, with very low rates of 
rejections. The patients, as would be anticipated, represent a range of ages, range of symptoms 
and number of symptoms, although it is interesting to note that nearly half of all patients 
referred were done so on the basis of one symptom. Importantly, from those referrals: 
 It is evidenced that across the three pathways, the proportion of VSP referrals resulting in 
a cancer diagnosis – the Conversation Rate (CR) – is 10.3%; 
 21.4% of patients were diagnosed with a new non-cancer condition; and, 
 Over half of patients received ‘normal’ test results and were discharged. 
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Of the cancers detected and diagnosed at the time of this work:  
 Over 14% were lung; 
 Over 10% haematological; 
 9% were prostate, colorectal or pancreatic; and, 
 A range of other cancers detected each in one individual patient.  
The cancers diagnosed by the VSP often fall into the category of Less Common and Rare – 68%, 
which is higher than the same category outcome from the MDC programme (Ace Programme, 
2019b, p.13).  
The staging of cancer diagnosis is important for patient outcomes. Evidence collated and 
analysed here illustrates that 35% were diagnosed at Stage 1 and 48% at Stage 4.  
 
5.2 Concluding observations 
The overarching aim of this Northern Cancer Alliance programme responds to a perceived 
problem for patients presenting at GPs with vague symptoms, creating a situation whereby GPs 
could struggle to identify an appropriate response and pathway. The aim of the pathways set up 
via this programme is to offer expedited access to testing and assessment for the patients with 
vague symptoms. Pathway objectives include reducing the time to diagnosis for patients and 
quickly screening out referred patients who do not need access to cancer treatment.  
The evidence presented above illustrates that the overall aim of the programme is being met – 
clearly, the pathways present a highly appropriate and effective option to GPs when faced with a 
patient with vague symptoms. It is also evidenced via the quantitative and qualitative data that 
expedited access is generally being achieved, with those who are staffing the pathways and 
associated activities feeling very positive about their effect and potential. Importantly, that 
expedited access is reducing the time to diagnosis for patients, thus enabling more rapid care, for 
cancer, or identifying another condition. That speed of diagnosis will also support treatment 
plans being enacted more quickly and, potentially, at an earlier stage in their cancer for some 
patients. It is also worthy of note that for a good proportion of patients referred, the rapidity of 
the system allows them to get the ‘all-clear’ quickly. There remain some outliers in outcome 
figures – in particular, the Sunderland data having only 32.8% compliance with the FDS standard. 
It may be that as the pathways continue to be refined and rolled out, and data reporting is more 
finely tuned, this compliance will rise. 
Overall, the evaluation team feel that the pathways considered here, at their individual stages, 
are successful, that the programme has been well implemented and is delivering against its core 
aims. However, in all programmes, particularly those that are piloting new approaches, lessons 
can be learned and, with this mind, below are a series of recommendations for the programme 







The NCA monitors uptake of the VSP by GP practices for the remainder of the project to identify 
whether further promotional activity needs to take place and to enable uptake rates to be 
captured by the programme or project leads.  
Recommendation 2:  
It would be useful for the programme commissioners to continue monitoring a number of 
metrics, to include: trends relating to GP practice size and proportion of VSP referrals; trends 
relating to GP practice size, age, deprivation profiles, ethnic diversity, geographic profile, are 
monitored with regard to equitable access or to provide information on performance and 
outcomes against different variables. 
Recommendation 3: 
Referral rejection rates are monitored throughout the project to identify whether repeat/revision 
of guidance on referral criteria or other action is needed.  
Recommendation 4: 
VSP configurations where minimal referral information is available and/or no clinic assessment is 
performed, consider how they can how they can obtain sufficient referral and patient 
information in order to evaluate referrals and monitor inappropriate referral rates. 
Recommendation 5: 
The age distribution, and particularly the frequency of patients < 50 years of age, is monitored 
and investigated if the current unexpected trend continues. 
Recommendation 6: 
The Project Steering Group considers whether co-morbidity data for all patients on the VSP is 
essential for interpreting project results and, if so, discuss with projects whether and how this 
data can be accessed and extracted. 
Recommendation 7: 
The Project Steering Group considers whether performance status data is essential for 
interpreting project results and, if so, discuss with projects whether and how this data can be 
accessed and extracted.  
Recommendation 8: 
The project(s) continue to monitor and investigate trends and variations in the percentage of 
patients presenting with each symptom type (and particularly GP gut feel) and reports this data 
on an individual project level as well as combined data for all VSPs. 
Recommendation 9: 
The Project Steering Group considers whether the Detection Rate of the pathway should be 




The Project Steering Group considers whether staging information linked to type of cancer 
should, and can be, provided by projects. If so, projects should be asked for staging information, 
linked to type of cancers for previous data returns. Furthermore, the data return form could be 
amended to capture this information for the remainder of the project. 
Recommendation 11: 
The Project Steering Group considers whether projects need to provide additional data to 
calculate the full range of metrics and, if so, to amend the data return form to collect this data. 
Recommendation 12: 
The Project Steering Group considers whether treatment information is required. If so, projects 
could be asked to provide treatment information relating to cancers diagnosed and reported to 
date, and the data form amended to collect this data. It is suggested that any amendment to the 
data collection form enables the type of cancer, staging and treatment to be linked.  
Recommendation 13: 
The Project Steering Group considers whether the VSP project needs to develop and implement a 
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Appendix 1 Patient Consultation 
 
Vague Symptoms Pathway Pilot Project – Patient Involvement Activities 
Provided by Jo Mackintosh, Macmillan Engagement and Co Design Project Manager 
 
There is growing recognition of the value that involving people in health services can bring 
including improving patient safety, the patient experience and health outcomes (NHS England: 
2017). However, it is essential that involvement activities are shown to be meaningful, have 
impact and are not tokenistic or regarded as a “nice to” activity. For this to happen, involvement 
needs to be fully embedded within NHS services and organisation’s and regarded as “usual 
business”. 
National policy documents such as Achieving World Class Cancer Outcomes (2015), the NHS 
Constitution (2015) and NHS Long Term Plan (2019) also recognise the importance of involving 
people in designing and delivering the changes necessary to drive forward improvements in 
cancer services. The Northern Cancer Alliance views patients, carers and members of the wider 
community as equal partners. It is committed to involving people at all levels of its work plan and 
demonstrating the value that involvement can bring. 
The patient involvement methodology adopted for the vague symptom’s pathway involved 
consulting with patients to measure their experience of care. The primary aim of this 
measurement was to understand which aspects of the pathway provided a positive patient 
experience and to identify where improvements could be made to further enhance the patient 
experience. 
Experiential data was collected from patients via a paper survey given to at the end of the 
pathway. The survey was developed by members of the individual project teams, the Cancer 
Alliance project manager and involvement lead. Survey questions were informed by the NHS 
Framework for Patient Experience (2011) and the identification of key patient “touchpoints” from 
across the pathway. Mapping of patient “touchpoints” spanned from the patient’s initial visit to 
the GP to the end of the pathway. Questions covered the following aspects of the patient 
experience: 
Primary Care: 
1. Access to care – patients are referred on to the vague symptom’s pathway in a timely 
manner. 
2. Information, education and communication – patients understand the purpose of the 
tests requested by their GP. 
3. Information, education and communication – patients understand the results of the 
tests requested by their GP. 
4. Information, education and communication – patients understand the purpose of a 
referral on to the vague symptom’s pathway. 
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5. Emotional support – the questions patients ask their GP are answered in a way they 
understand. 
Secondary Care: 
1. Information, education and communication – patients understand the purpose of the 
tests requested by hospital staff. 
2. Information, education and communication – patients understand the results of the 
tests requested by hospital staff. 
3. Emotional support – the questions patients ask hospital staff are answered in a way 
they understand. 
4. Coordination and integration of care – patients experience continuity of care when 
referred from the vague symptoms to a tumour specific pathway, back to their GP or 
other health care services. 
Overall: 
1. Respect for patient-centred values, preferences, and expressed needs – patients feel 
involved in the decisions made at each stage of their care. 
Qualitative and quantitative data was collected from patients at two of the vague symptom 
pathway pilot sites (Sunderland and South Tees). Data collection was overseen by members of 
the project team at each of the sites. Each pilot site was provided with a standardised Excel 
spreadsheet data analysis tool. This tool produced quantitative results on a monthly basis and 
provided a repository for qualitative data. Quantitative data analysis provided pilot sites with the 
opportunity to track their performance over time in both primary and secondary care settings. 
Data from both pilot sites was fed back to the vague symptoms pilot steering group.  
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